NBER WORKING PAPER SERIES

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS
Kristian R. Miltersen
Eduardo S. Schwartz
Working Paper 10258
http://www.nber.org/papers/w10258
NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
January 2004

We are grateful for discussions at Vanderbilt University, Simon Frazer University, University of Utah,
European Finance Association‚Äôs annual meeting (August 2003), Odense University, Norwegian School of
Economics and Business Administration, and at Symposium on Dynamic Corporate Finance and Incentives,
Copenhagen Business School. We are grateful to Bart Lambrecht, Grzegorz Pawlina, and seminar participants
for valuable comments and suggestions. Miltersen gratefully acknowledges financial support of Storebrand.
Document typeset in LATEX. The views expressed herein are those of the authors and not necessarily those
of the National Bureau of Economic Research.
¬©2004 by Kristian R. Miltersen and Eduardo S. Schwartz. All rights reserved. Short sections of text, not to
exceed two paragraphs, may be quoted without explicit permission provided that full credit, including ¬©
notice, is given to the source.

R&D Investments with Competitive Interactions
Kristian R. Miltersen and Eduardo S. Schwartz
NBER Working Paper No. 10258
January 2004
JEL No. G31, O32, O22
ABSTRACT
In this article we develop a model to analyze patent-protected R&D investment projects when there
is (imperfect) competition in the development and marketing of the resulting product. The
competitive interactions that occur substantially complicate the solution of the problem since the
decision maker has to take into account not only the factors that affect her/his own decisions, but
also the factors that affect the decisions of the other investors. The real options framework utilized
to deal with investments under uncertainty is extended to incorporate the game theoretic concepts
required to deal with these interactions. Implementation of the model shows that competition in
R&D, in general, not only increases production and reduces prices, but also shortens the time of
developing the product and increases the probability of a successful development. These benefits
to society are countered by increased total investment costs in R&D and lower aggregate value of
the R&D investment projects.
Kristian R. Miltersen
Norwegian School of Economics and Business Administration
Department of Finance and Operations Research
Helleveien 30
N-5045 Bergen
Norway
kristian.r.miltersen@nhh.no
Eduardo S. Schwartz
Department of Fianc√©
Anderson Graduate School of Management
110 Westwood Plaza
Box 951481, UCLA
Los Angeles, CA 90095-1481
and NBER
eschwart@anderson.ucla.edu

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

2

1. Introduction
Among all types of investment projects patent-protected R&D (research and development) investment
projects pose one of the most diÔ¨Écult tasks for evaluators. The main reason for this is that there are
multiple sources of uncertainty in R&D investment projects and that they interact in complicated ways.
The problem is so complex that until recently it was not possible, even with numerical methods, to analyze
them. The development of numerical simulation methods that deal with optimal stopping time problems
(LongstaÔ¨Ä and Schwartz 2001) has now made this possible.
R&D investment projects typically take a long time to complete and since there is a learning process about
the R&D project as investments proceed, there is large uncertainty about the investment costs required for
the R&D project. There is not only uncertainty about the total costs of the development, but also about
the time it will take to complete the development. In essence, there is learning while investing. Moreover,
during the development phase there exists a possibility that exogenous factors such as political or technical
disasters can put an end to the R&D investment project. These type of catastrophic events are very common
in R&D investment projects because of the long investment time horizon.
Once the development phase is completed, the resulting product is produced and marketed. During this
marketing phase there is uncertainty about the demand for the product as well as the supply of competing
products. Seen from the start of the development phase these uncertainties are magniÔ¨Åed by the fact that
it is not even clear what the exact product that comes out of the R&D investment project would be. In
addition, if the resulting product is patent-protected and the patent is obtained during the development
phase of the R&D investment project, there will be uncertainty not only about the level of the cash Ô¨Çows
produced, but also about the duration of these cash Ô¨Çows since the starting date of the marketing phase is
uncertain but the expiration date of the patent is Ô¨Åxed.
The possibility of competing products during the marketing phase plays a crucial role for the R&D
investment decisions during the development phase since also the competing products have to go through a
similar development phase. Moreover, competition in the development phase feeds back into the marketing
phase in the sense that the competitive interactions in the development phase may have the eÔ¨Äect that some
of the competitors terminate their R&D investment projects even before they complete their development.
In this article we develop a model to analyze patent-protected R&D investment projects that takes into
account all the sources of uncertainty described above. In particular, we combine elements of real options
theory with equilibrium concepts from game theory to study this problem where the R&D investment
decisions of one player depend critically on the decisions of the other players. These competitive interactions

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

3

aÔ¨Äect the valuation problem both in the development phase and in the marketing phase. The possibility of
an oligopolistic outcome in the marketing phase aÔ¨Äects the decisions taken by the players in the development
phase.
We have concretized our problem by taking as an example an R&D investment project from the pharmaceutical industry. This is a particularly interesting problem since the investments required to develop a
new drug are in the magnitude of hundreds of millions of dollars and typically take more than ten years to
complete. Moreover, these R&D investment projects are usually patent protected at a very early stage of
the development phase. Without taking competitive interactions into account Schwartz and Moon (2000)
and Schwartz (2001) have also studied R&D investment projects in the pharmaceutical industry using a
real options framework. In this article we mainly focus on the competitive interactions between competing
Ô¨Årms. In the monopoly situation the owner of the R&D investment project can assume that the probability
distribution of the underlying is exogenously given, whereas in the oligopoly situation the decisions of all
players aÔ¨Äect this probability distribution. Hence, the probability distribution of the underlying becomes
endogenous and it is therefore part of the equilibrium outcome.
Many of the aspects of our R&D investment problem have been analyzed separately in a number of
articles in the literature. Grenadier and Weiss (1997) and Bernardo and Chowdhry (2002) concentrate on
the experience obtained in the investment process, but do not consider competitive interactions. The idea
is that the option to invest is also an option to get more experience with a certain technology, i.e. learning
by investing, and that this should be taken into account when analyzing the optimal time to invest. The
aspect of competition is considered by Williams (1993), who analyzes the competitive exercise of options
to invest. The main point is that as more investors exercise their options, the less attractive it is for other
investors to exercise their options because of a downward sloping demand curve. The aspect of competition
and especially the problem of coordinating the investment behavior is further analyzed by Huisman and
Kort (1999) and Huisman, Thijssen, and Kort (2001). Huisman and Kort (1999) argue that the perfect
coordination between the competing investors assumed by Williams (1993) is not an equilibrium outcome
without cooperation between investors; in a non-cooperative setting it can happen in equilibrium that more
than one investors invest simultaneously. Huisman, Thijssen, and Kort (2001) generalize these results by
allowing for mixed strategies by competing investors. The aspect of asymmetric competing Ô¨Årms is analyzed
by Pawlina and Kort (2001). Smit and Ankum (1993) is the Ô¨Årst article to combine sequential investment
options with competitive issues. Their discrete two-period binomial model captures some of the same features
as our model. A similar model but in continuous time is developed by Baldursson (1998), who shows that

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

4

the problem can also be solved as a central-planner problem for a speciÔ¨Åcally engineered Ô¨Åctitious social
planner. Finally, Grenadier (2002) adds a time-to-build feature to this model. The models in the last three
articles have in common that investors have a number of capacity options they can exercise. In deriving the
optimal exercise strategy for these capacity options investors take into account both the impact that their
own exercise strategy, as well as the exercise strategies of the other investors, have on the market. None of
these models have the feature of a Ô¨Ånite time horizon, which is essential to deal with patents with Ô¨Ånite life.
Since these models deal with capacity expansion, they do not distinguish between a development phase and
a marketing phase, which is critical in R&D investment projects. Some of these models capture learning
by investing in the sense that exercising an investment option reveals more information; Grenadier (2002)
adds a time-to-build feature in the sense that it takes a certain amount of time from when the decision to
exercise an option is taken and until the pay oÔ¨Ä is realized. But none of the models capture learning while
investing in competitive markets in the sense that investments take time and information is revealed while
investing, so that it can become optimal to abandon the investment project even before completion because
of competitive interactions.
Grenadier (1999) and Lambrecht and Perraudin (1999) introduce asymmetric information issues in the
competitive exercise of options to invest. In these one-investor-one-option models there are no compound
option aspects. Grenadier (1999) shows that asymmetric information can lead to informational cascades.
Lambrecht and Perraudin (1999) concentrate on preemption in winner-takes-it-all competitive investment
games.
In our model we consider two Ô¨Årms which are investing in R&D for two diÔ¨Äerent drugs targeted to cure
the same disease, so that if both are successful they would have to share the same market. The fact that,
if both are successful, they will obtain duopoly proÔ¨Åts instead of monopoly proÔ¨Åts in at least part of the
marketing phase of the product, implies that during the development phase, each Ô¨Årm will take into account
not only its own situation but also the situation of its competitor, to make its R&D investment decisions.
The costs to completion of the R&D investment project for each Ô¨Årm are assumed to follow stochastic
processes through time with two types of shocks, i.e. technical shocks, which are idiosyncratic to each Ô¨Årm,
and input cost shocks, which are common to both Ô¨Årms. In addition, during the development phase there is
a Poisson probability of catastrophic events for each R&D investment project in the sense that it may have
to be terminated because of some terrible side eÔ¨Äect in the clinical trials or other reasons. The winning firm,
that is, the Ô¨Årm that Ô¨Årst successfully completes the R&D investment project, starts receiving monopoly
proÔ¨Åts in the sale of the drug until the losing firm eventually completes the R&D investment project, at

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

5

which point both Ô¨Årms share the duopoly proÔ¨Åts from the sale of the drug. The demand for the drug is
also stochastic and we assume that the demand shocks follow a geometric Brownian motion. We allow also
for the input cost shocks, common to both R&D investment projects, to be correlated with the demand
shocks since both can depend on general market conditions. The equilibrium investment and production
strategies for both Ô¨Årms are derived in a Cournot-Nash framework. During the development phase we focus
for each Ô¨Årm on the optimal stopping time to exit the R&D investment project which represents the optimal
exercise of the option to abandon the R&D investment project. Note that the optimal exercise strategy
for the abandonment option for one Ô¨Årm depends on the exercise strategy of the other Ô¨Årm and vice versa,
so that the values of both R&D investment projects and the optimal exercise strategies have to be solved
simultaneously.
While the problem is initially formulated in continuous time, it is solved using a discrete time approximation. Since there is no closed form solution to the complex problem we formulate, we solve the problem
using numerical simulation methods. We apply an extended version of the least-squares approach proposed
by LongstaÔ¨Ä and Schwartz (2001) for valuing American options, to determine the optimal stopping time for
both Ô¨Årms, taking into account the competitive interactions.
For comparative purposes, when we report the results of the analysis for the duopoly situation, we also
report the corresponding results for the monopoly situation. The monopoly situation corresponds closely
to the real option problem solved by Schwartz (2001). However, in order to make this comparison more
fair to the monopoly situation in our model, the monopolist has access to both R&D investment projects.
Obviously, the monopolist will invest in the most valuable of the two projects, but, in addition, she/he
has the option to invest in the second project as a backup project. The value of a backup project to the
monopolist is, however, limited in the sense that she/he will only get beneÔ¨Åts from the project if either the
main project is hit by a catastrophic event or if it turns out that the main project is more expensive to
develop than the backup project.
In reporting the results we mainly concentrate on the symmetric case, that is, when both R&D investment
projects are identical in the duopoly situation. Though the computer program we have developed to solve
the problem numerically is able to handle a great deal of generality, most of the interesting insights of the
model can be better observed in the symmetric case. Without loss of generality, we concentrate on the case
where the patents for both competitive drugs expire at the same date. If, on the other hand, the patents
have diÔ¨Äerent expiration dates, there is no value in the second patent protection when the Ô¨Årst patent expires
since generic drugs related to the Ô¨Årst drug will be introduced and be able to compete with the second drug.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

Pre patents
R&D phase

Competitive
R&D phase:
both firms
Both firms
invest in
take out
post patents
their patents R&D

0

First drug
marketed
œÑ

Monopoly
phase:
winning firm
earns
monopoly
profit, losing
firm still
invests in
post patents
R&D

Second drug
marketed

Duopoly
phase: both
firms earn
duopoly
profit

œÑ

6

Patents
expire

Perfect
competition
phase: zero
profit to
both firms

-

t

T

Figure 1. Time line of our model.

The model provides some interesting results with potentially important policy implications. As expected,
the value of the R&D investment project to the monopolist is higher than the aggregate value of the R&D
investment projects for both duopolists since both have to share the same demand. Unless the R&D investment projects are very marginal, the amount produced is on average higher for the duopolists, not only
because when both are producing simultaneously they produce a larger amount (at a lower price), but also
because the probability that at least one of the duopolists eventually produces is higher than the probability
that the monopolist produces, and on average the time until the Ô¨Årst project is completed is shorter. If the
R&D investment projects are very marginal competition in R&D can actually harm the development if there
is no mechanism to select which of the two duopolists who should invest and who should abandon. Hence,
if the objective of the policy maker or regulator is to promote the production of the largest possible amount
of drugs at the lowest possible price in the shortest period of time, competition in R&D accomplishes this
objective in most cases. Only in the cases where the R&D investment projects are very marginal can it be
beneÔ¨Åcial to protect one single developer from competition in order to accomplish these goals. One should,
in addition, have in mind that the total costs to R&D are higher in the duopoly situation and that the
value of the R&D investment projects is lower. The model presented can also be used to derive other policy
implications such as the eÔ¨Äect of subsidies or drug price and/or quantity commitments on the amount of
R&D investments.
The article is organized as follows. Section 2 presents the model and derives the Cournot-Nash type
equilibrium. Section 3 explains the numerical solution procedure used in the implementation of the model.
Section 4 describes the numerical results and performs sensitivity analysis of these results with respect to key
parameters of the model. Finally, Section 5 summarizes the article and provides some concluding remarks.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

7

2. The Model
We assume that two Ô¨Årms are each investing in R&D for a drug that is targeted to cure the same disease.
Both Ô¨Årms take out a patent on their speciÔ¨Åc drug at date zero based on their earlier (pre patents) R&D.1
The two patents are based on diÔ¨Äerent molecules and will lead to diÔ¨Äerent drugs, but both drugs are targeted
to cure the same disease. Before the drugs can be marketed, some post patents R&D must be conducted
(further research, development, testing, clinical trials, etc.). When the Ô¨Årst drug is marketed, the drug will
be protected from competition by the patent so that the owner would be able to earn a monopoly proÔ¨Åt until,
eventually, the second Ô¨Årm markets its competing drug. When that second drug is marketed, the two Ô¨Årms
will still be protected from further competition by their two patents. Hence, the two Ô¨Årms have the only two
drugs for this disease and will therefore be able to earn a duopoly proÔ¨Åt.2 This situation continues until the
two patents expire.3 When this happens, we assume that generics will Ô¨Çood the market and drive all proÔ¨Åts to
zero in a perfect competitive market setting.4 The whole time line of our model is summarized in Figure 1.
The important decision variables for our two Ô¨Årms are the post patents R&D investment/abandonment
decisions. That is, based on the information of both the Ô¨Årm‚Äôs own and its competitor‚Äôs estimated remaining
R&D investments and forecasts of the demand for the drug, each Ô¨Årm must consider whether it is worthwhile
for it to continue investing in R&D or whether it should abandon its R&D investment project. In order to
solve that problem we Ô¨Årst have to develop a model for the consumption market where the drug is eventually
going to be sold.
We start by modeling the market for drugs for a given disease. We assume that the price of the drug,
denoted Pt , at any given date, t, is given by
Pt = Yt Q(qt ),
when the date t instantaneous production rate is qt . Here Y is an exogenously given stochastic process that
models demand shocks to the model. That is, Y captures stochastic shocks that change the demand of the
drug, e.g., epidemics, acts of terror, development of vaccines, non-anticipated alternative drugs, etc. We

1

The assumption that both Ô¨Årms take out their patents at the same date is not important. The game could also (without loss
of generality) start at the date when the second Ô¨Årm takes out its patent.
2
Note that here we have abstracted from the fact that one of the drugs may be more eÔ¨Écient than the other and, thus, may
capture a larger share of the market.
3
If the two patens do not expire on the same date, then this situation only continues until one of the two patents expire.
4
It would be easy to introduce some terminal value to the R&D investment projects at the expiration of the patent period.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

8

Q(q)
20

Q

15

10

5

qiD q M

qD

0
0

2

4

6

8

10

12

q

Figure 2. The inverse demand function, Q(¬∑), from equation (1) for a = 15 and b = 0.1.
The optimal production rates, q M and qiD , for the monopoly and the duopoly situations are
marked together with the total production rate in the duopoly case, q D .

assume Y follows a geometric Brownian motion under an equivalent martingale measure, Q, i.e.5
dYt = ¬µy Yt dt + œÉy Yt dWty ,

Y0 = 1,

where ¬µy and œÉy are given constants parameterizing the drift and volatility of the demand shocks and W y
is a standard Brownian motion under an equivalent martingale measure, Q.6 Q(¬∑) is the inverse demand
function for the drug (except for Yt ) and we assume it has the following form
(1)

2

Q(q) ‚â° ae‚àíbq ,

q ‚â• 0,

where a and b are positive constants. We have chosen this speciÔ¨Åc form of the inverse demand function since
it gives internal optimal solutions even without variable production cost rates both for the monopoly and

5Since in this article we pursue the valuation and the optimal R&D investment/abandonment strategies, we only need to model

our stochastic processes under an equivalent martingale measure, Q.

6Formally, deÔ¨Åne the probability space (‚Ñ¶, F , Q) and a Ô¨Åltration, F ‚â° {F }
t t‚àà[0,T ] , which we will concretize later, that fulÔ¨Ålls the

usual conditions. All stochastic processes we deÔ¨Åne in this article, including Y and W y , are implicitly assumed to be adapted
to F.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

9

duopoly supply situations.7 For a = 15 and b = 0.1 we have depicted the inverse demand function, Q(¬∑), in
Figure 2.
If there is only one Ô¨Årm which has monopolistic supply of the drug at date t, this Ô¨Årm would simply
control the production rate, qt , to maximize the instantaneous proÔ¨Åt rate, Œ†t , given by
2

Œ†t ‚â° Pt qt = Yt aqt e‚àíbqt .
Note again that for simplicity we have assumed that the variable direct production cost rate is zero. The
optimal monopoly production rate at date t, q M , is easily derived as
1
qM = ‚àö ,
2b
which is independent of t. Since in the monopoly case there is only one Ô¨Årm producing, this production rate
will also be the total production rate at any date. It implies a monopoly price at date t of
a
PtM = ‚àö Yt
e
and a monopoly proÔ¨Åt rate at date t of
a
Yt .
Œ†M
t = ‚àö
2be
The superscript M indicates monopoly.
If there are two Ô¨Årms, indexed one and two, competing for selling drugs to cure the same disease at date
t, we assume that these two Ô¨Årms compete in a Cournot competitive fashion. In order to calculate the
corresponding market equilibrium we Ô¨Årst would have to calculate the two Ô¨Årms‚Äô response functions. Given
Ô¨Årm j ‚àà {1, 2} has set its production rate at date t to qjt , consider the problem of Ô¨Ånding the optimal
production rate for the other Ô¨Årm, which is indexed i = 3 ‚àí j,8 at date t. Given Ô¨Årm j ‚àà {1, 2} has set its
production rate at date t to qjt , Ô¨Årm i = 3 ‚àí j should maximize its instantaneous proÔ¨Åt rate at date t as a

7For simplicity we assume that variable production costs are zero, because this signiÔ¨Åcantly simpliÔ¨Åes our analysis. Basically,

the only role for the inverse demand function, Q, is to provide two diÔ¨Äerent production levels, one for the situation where there
is only one producer, the monopoly situation, and one for the situation where there are two producers, the duopoly situation.
Production costs would only matter for the decision of how much to produce when the drug is marketed. If there are positive
production costs, the inverse demand function, Q, should just be altered so that it gives the two optimal production rates as
solutions when the production costs are included in the optimization and so that the corresponding function values are the
proÔ¨Åt rates. The whole analysis can then be carried out the same way as it is in the article. In the pharmaceutical industry
variable production cost rates have little importance relative to R&D investment costs. That is, variable production cost rates
can be neglected from the problem without any signiÔ¨Åcant alterations of the qualitative conclusions from our analysis.
8There are exactly two Ô¨Årms in our model, indexed one and two. Hence, if one Ô¨Årm has index j ‚àà {1, 2}, the other Ô¨Årm must
be indexed 3 ‚àí j.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

10

function of its own production rate, qit ,
2

Œ†it ‚â° Pt qit = Yt aqit e‚àíb(qit +qjt ) .
The response function for Ô¨Årm i‚Äôs production rate at date t is easily derived as

‚àó
qit
(qjt ) =

2 +2
bqjt
qjt
‚àí
.
4b
2

By symmetry we know that the response functions for both Ô¨Årms are identical. The unique Nash equilibrium
production rate at date t in a Cournot duopoly setting is then the (unique) Ô¨Åx point of the function

q(q) ‚â°

bq 2 + 2 q
‚àí ,
4b
2

which is again independent of t. Hence, the equilibrium production rate at date t for each of the two Ô¨Årms
can easily be derived as
1
qiD = ‚àö ,
2 b

i ‚àà {1, 2}.

Hence, the total duopoly production rate will be
qD =

2


1
qiD = ‚àö ,
b
i=1

the duopoly price at date t will be
PtD =

a
Yt ,
e

and the duopoly proÔ¨Åt rate at date t to each of the two Ô¨Årms will be
Œ†D
it =

a
‚àö Yt ,
2e b

i ‚àà {1, 2}.

The superscript D indicates duopoly. Note that the total production rate at date t has increased by a factor
‚àö
2 ‚âà 1.41 from ‚àö12b in the monopoly case to ‚àö1b in the duopoly case and at the same time the price has

‚àö
dropped by a factor e ‚âà 1.65 and total proÔ¨Åt rates have dropped by a factor 2e ‚âà 1.17, see Figure 2.
If there is perfect competition, standard microeconomic arguments give that the proÔ¨Åt of each (identical)
Ô¨Årm is driven to zero. In our model we have assumed that variable production cost rates are zero so this
means that the sum of the production rates for all the Ô¨Årms would converge to inÔ¨Ånity and the corresponding

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

11

equilibrium price for the drug would be zero. That is,
q P C ‚â° ‚àû,
PtP C = 0,
and

C
Œ†P
it ‚â° 0,

i ‚àà N.

The superscript P C indicates perfect competition.
This characterizes the situation our two Ô¨Årms will face when their respective R&D investment projects
eventually develop into a drug that can be marketed. That is, in real options terms we have characterized the
underlying security. However, in order to develop the drug the Ô¨Årms have to go through an uncertain phase
of R&D. At date zero when the Ô¨Årms take out their patents, each of the two Ô¨Årms has an estimate of the
costs of the remaining R&D investments, K10 and K20 , that they each still have to conduct. These estimates
of remaining R&D investment costs are assumed to be public information, i.e. common knowledge.9 At any
given date t the estimated remaining R&D investment costs for Ô¨Årm i ‚àà {1, 2} is given by the stochastic
variable, Kit . For tractability we assume that the whole process of past and present estimated remaining
R&D investment costs, {(K1s , K2s )}s‚àà[0,t] as well as the past and present values of the demand shock process,
{Ys }s‚àà[0,t] , are public information. As long as Ô¨Årm i has not yet abandoned its R&D investment project,
the stochastic process, Ki , for i ‚àà {1, 2}, develops over time under an equivalent martingale measure, Q,
according to the stochastic diÔ¨Äerential equations
(2)

dKit = ‚àíIi dt + Œ≥i



Ii Kit dzti + ¬µik Kit dt + œÉik Kit dWtk .

Here z 1 , z 2 , and W k are standard Brownian motions under Q. The Ô¨Årst term in equation (2) reÔ¨Çects the
rate at which the Ô¨Årm invests in R&D for the drug at date t.10 Since the decision to continue investing
in R&D is an irreversible decision, the current investment rate, Ii , must at any date t be non-negative.
Furthermore, since it takes time to conduct R&D, the current investment rate, Ii , must at any date t be
Ô¨Ånite. The second term in equation (2) reÔ¨Çects the uncertain nature of the R&D process itself over time
9In this article we have abstracted from the interesting issues arising from asymmetric information, and concentrated our

attention on capturing the competitive interactions.

10Purely for expositional simplicity we have assumed that the investment rate of Ô¨Årm i is a constant, I . In our numerical
i

implementation of our model, cf. Section 3, it could as well have been a deterministic function of time or even a deterministic
function of the current values of the governing state variables.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

12

due to technical uncertainty. The more R&D investments the Ô¨Årm estimates it still has to conduct and the
higher the current R&D investment rate is, the more uncertainty will be revealed per time unit. Moreover,
we assume that these type of technical shocks are independent between the two Ô¨Årms and also independent
of the demand shocks and the R&D input cost shocks. That is, z 1 and z 2 are independent of each other and
also independent of W y and W k .11 Œ≥i is a Ô¨Årm speciÔ¨Åc volatility parameter measuring the size of technical
shocks. The two last terms in equation (2) reÔ¨Çect that the estimated remaining R&D investment costs vary
not only because of technical shocks but also because of general uncertainty in the surrounding market, e.g.,
labor costs, input costs to the R&D process, etc. We assume that these input cost shocks are the same for
both Ô¨Årms; thus it is the same Brownian motion, W k , that enters into both Ô¨Årms‚Äô estimated remaining R&D
investment cost processes. Moreover, W k may be correlated with W y to reÔ¨Çect that the general market
conditions are also related to the demand of the drug.12 That is, we assume
dW y , W k t = œÅyk dt.
The drift terms ¬µik and volatility terms œÉik parameterize the uncertainty in the surrounding market, which
may be diÔ¨Äerent for the two Ô¨Årms. For example, Ô¨Årm speciÔ¨Åc expected increases in labor costs and input
costs over time is parameterized via ¬µik . At date zero when the Ô¨Årms take out their patents, their estimated
remaining R&D investment costs are of course positive, so Ki0 > 0, i ‚àà {1, 2}. The speciÔ¨Åcation of the
development of the estimated remaining R&D investment costs from equation (2) is very similar to the
speciÔ¨Åcations used in Pindyck (1993), Schwartz and Moon (2000), and Schwartz (2001).13
Schwartz and Moon (2000) and Schwartz (2001) consider also the possibility of catastrophic events. This
reÔ¨Çects the fact that besides costs uncertainty and demand uncertainty there is also a risk that the R&D
investment project can simply fail for other reasons independent of how much the Ô¨Årm invests in it and
independent of how high the demand for the drug will be. It may be that the clinical trials reveal that

11This assumption is not essential, but it simpliÔ¨Åes the development of the model.
12Both positive and negative correlations as well as no correlation are economically plausible. A positive correlation could be

explained by a higher than expected demand for the drug if the general economy booms, which would then also lead to higher
than expected input costs to the R&D investment project. This would, e.g., be the case for a drug like Insulin. A negative
correlation could be explained by a higher than expected demand for the drug if the general economy ends up in a recession.
This would be the case for a drug like Prozac. Naturally, there are also cases where there is no connection between the demand
for the drug and the general state of the economy. In our main numerical examples in Section 4 we use a small negative
correlation, but we also perform sensitivity analysis with respect to this correlation parameter.
13It should be pointed out that the models in these articles are formulated as stochastic optimal control problems, whereas
our problem is formulated as an optimal stopping time problem. The optimal solutions to these stochastic optimal control
problems are typically bang-bang solutions and therefore they are very similar to the solution obtained by solving an optimal
stopping time problem. However, the optimal stopping time solution does not allow for costless temporary shut-down of the
R&D investment project. Since we are dealing here with a Ô¨Ånite time horizon, the option to temporary shut down is not
important and, in addition, probably unrealistic for a drug development project.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

13

K1 and K2
140

120

100

K

80

60

40

20

0
0

5

R&D

10

M
t

15

D

20

PC

25

Figure 3. Illustrative sample paths of the two estimated remaining R&D investment cost
processes, K1 and K2 , from equation (2) for K10 = K20 = 100, I1 = I2 = 10, Œ≥1 = Œ≥2 = 0.2,
¬µ1k = ¬µ2k = 0, and œÉ1k = œÉ2k = 0.1. In these sample paths we have assumed that both R&D
investment projects continue until their corresponding estimated remaining R&D investment
cost processes, K1 and K2 , hit zero. The competitive R&D phase (marked R&D) takes
place in the time period from date zero and until the Ô¨Årst process hits zero around date
10.6. The monopoly phase (marked M) takes place in the time period from when the Ô¨Årst
process hits zero around date 10.6 and until the second process hits zero around date 16.6.
Finally, the duopoly phase (marked D) takes place in the time period from when the second
process hits zero around date 16.6 and until the patents expire at date T , which is 20 years
in this example. After date T (20 years) the perfect competition phase (marked PC) takes
over.

the drug has some terrible side eÔ¨Äects, it may turn out that it simply is not technically feasible to develop
the drug, it may be that the government prohibits certain classes of drugs, etc. We model this type of
catastrophic events as two Poisson processes, denoted Q1 and Q2 , one for each Ô¨Årm, with intensities Œª1 and
Œª2 . These two Poisson processes are independent of each other and also independent of the other three
governing state variables, K1 , K2 , and Y . For tractability we also assume that past and present values of
the Poisson processes, {(Q1s , Q2s )}s‚àà[0,t] , are public information.
We have depicted illustrative sample paths of the two estimated remaining R&D investment cost processes,
K1 and K2 , in Figure 3 in an example where both Ô¨Årms are exactly equal (the symmetric case): both Ô¨Årms
have at date zero estimated remaining R&D investment costs of 100 (K10 = K20 = 100) and both invest

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

14

10 per year in R&D (I1 = I2 = 10). Both Ô¨Årms face technical shock volatility of 20% (Œ≥1 = Œ≥2 = 0.2) and
equal drift and volatility parameters of the input cost shocks to the R&D investment project of zero and 10%
(¬µ1k = ¬µ2k = 0 and œÉ1k = œÉ2k = 0.1). In these sample paths we have assumed that the R&D investment
projects continue until the corresponding estimated remaining R&D investment cost processes, K1 and K2 ,
hit zero. The competitive R&D phase (marked R&D in Figure 3) takes place in the time period from date
zero and until the Ô¨Årst process hits zero around date 10.6. The monopoly phase (marked M in Figure 3)
takes place in the time period from when the Ô¨Årst process hits zero around date 10.6 and until the second
process hits zero around date 16.6. Finally, the duopoly phase (marked D in Figure 3) takes place in the
time period from when the second process hits zero around date 16.6 and until the patents expire at date
T , which is 20 years in this example. After date T (20 years) the perfect competition phase (marked PC
in Figure 3) takes over. Cf. Figure 1 for the complete time line of our model. The parameter values used
to create Figure 3 are identical to the ones that we will use in our numerical examples in Section 4. Note
that the four phases of our model, the competitive R&D phase, the monopoly phase, the duopoly phase, and
the perfect competition phase, are deÔ¨Åned based solely on the development of the two estimated remaining
cost processes, K1 and K2 . Because of optimal abandonment of the R&D investment project and/or the
occurrence of catastrophic events, it may very well be the case that there is only one Ô¨Årm (or even no Ô¨Årms)
producing drugs in the duopoly phase. Similar things can happen in the other phases. The names of the
diÔ¨Äerent phases are based on what would have happened if there were no abandonment and the catastrophic
events never occurred. The reader should only use the names of the diÔ¨Äerent phases to be able to distinguish
the four phases of the model and not necessarily as a statement of what type of economic activity that will
occur in these phases.
The drug developed by Ô¨Årm i ‚àà {1, 2} is marketed as soon as the corresponding (estimated) remaining
R&D investment cost process, Ki , hits zero unless either an optimal abandonment decision has been taken
earlier on or catastrophic events have occurred to the R&D investment project earlier on.14 In order to keep
track of when this happens we introduce some stopping times.15 DeÔ¨Åne œÑi to reÔ¨Çect when Ô¨Årm i‚Äôs product
will be marketed, i ‚àà {1, 2}, if its project is still alive, i.e., if neither an optimal abandonment decision has
been taken earlier on nor catastrophic events have occurred to the R&D investment project earlier on. As a

14We place estimated in parentheses because when the (estimated) remaining R&D investments are exactly zero, they are not

just estimates any more, they are truly zero: the drug is ready.

15Formally, a stochastic variable, œÑ , is a stopping time related to the Ô¨Åltration F if the event {œÑ ‚â§ t} ‚àà F , for all t ‚àà [0, T ].
t

Moreover let S(F) denote the set of all stopping times related to the Ô¨Åltration F. For the rest of the article the Ô¨Åltration F will
be the Ô¨Åltration generated by the governing state variables, i.e. Ft = œÉ{(Ys , K1s , K2s , Q1s , Q2s )|s ‚àà [0, t]}.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

15

Ô¨Årst attempt we can specify this as
inf{t ‚â• 0|Kit = 0}.
However, the patents the Ô¨Årms take out at date zero have a certain life span, normally twenty years, which
we here denote T . If none of the two Ô¨Årms have been able to market a drug within that life span, they will
not be able to derive any proÔ¨Åts from their R&D eÔ¨Äort. There are many possible scenarios leading to that
conclusion. One of them is that if they continue their R&D eÔ¨Äort even after date T and eventually market
their drug, an instant later the generics are ready with competing drugs because the patents have already
expired. So they will not be able to derive any proÔ¨Åts from their R&D eÔ¨Äort. A more likely scenario is the
following: since it would never be optimal to continue the R&D investment projects after date T , the R&D
investment project will be abandoned at date T at the latest, and very likely much earlier. Hence, there will
be no drugs marketed and therefore no generics either. Again, they will not be able to derive any proÔ¨Åts
from their R&D eÔ¨Äort. Thus, our stopping times are only interesting when they are strictly smaller than
T since there can be derived no proÔ¨Åts after date T . That is, we would like to reÔ¨Åne our deÔ¨Ånition of œÑi ,
i ‚àà {1, 2} to16



œÑi ‚â° min inf{t ‚â• 0|Kit = 0}, T .

Hence, the monopoly phase starts at date œÑ deÔ¨Åned as
œÑ ‚â° min{œÑ1 , œÑ2 },
and the duopoly phase starts at date œÑ deÔ¨Åned as
œÑ ‚â° max{œÑ1 , œÑ2 }.
As long as the Ô¨Årms are still investing in R&D, they can decide to abandon their R&D investment project if
they Ô¨Ånd that it is not proÔ¨Åtable to continue. We will denote the stopping time when the Ô¨Årms stop investing
in their R&D investment projects for economic reasons by ŒΩi , i ‚àà {1, 2}.17 Surely, they will stop investing no
later than when their R&D investment project is completed, hence ŒΩi ‚â§ œÑi . The event {ŒΩi = œÑi } now means
that the Ô¨Årm did not Ô¨Ånd it optimal to abandon its R&D investment project before completion, whereas

16We do not include the catastrophic events into our stopping times since these are much more eÔ¨Éciently dealt with explicitly by

multiplying the relevant expressions with the probability that the catastrophic events will occur under an equivalent martingale
measure, Q.
17We still do not include catastrophic events into our stopping times, cf. footnote no. 16.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

16

the event {ŒΩi < œÑi } means that the Ô¨Årm did Ô¨Ånd it optimal to abandon its R&D investment project before
completion.18
We are now ready to more formally set up the objectives of the two Ô¨Årms. DeÔ¨Åne the winning Ô¨Årm as the
Ô¨Årm which, if its project is alive, markets its drug at the entrance date into the monopoly phase and let w
denote the index of the winning Ô¨Årm. That is,

w‚â°

Ô£±
Ô£¥
Ô£¥
Ô£≤1,

œÑ1 = œÑ ,

Ô£¥
Ô£¥
Ô£≥2,

œÑ1 = œÑ .

Moreover, let l denote the index of the losing Ô¨Årm, i.e., the Ô¨Årm which, if its project is alive, markets its
drug at the entrance date into the duopoly phase.19 That is,
l ‚â° 3 ‚àí w.
In order to Ô¨Ånd the values of the two Ô¨Årms‚Äô R&D investment projects as well as their optimal R&D
investment/abandonment strategies we have to value their projects in all three phases of our model starting
from the last phase, i.e. the duopoly phase. At the entrance date into the duopoly phase there are three
possible situations: there can be either two, one, or no projects alive to be marketed. If there are still two
projects alive to be marketed at the entrance date into the duopoly phase, the Ô¨Årms will compete in the
usual Cournot fashion. At any given date t in the duopoly phase, i.e. t ‚àà [œÑ , T ), the total value to each of

18Note that the estimated remaining R&D investment costs at date t, K are not (necessarily) in any precise mathematical
it

sense equal to the expected remaining R&D investment costs. That is, in general Kit is not equal to

ŒΩi
EQ
e‚àí(r+Œªi )(s‚àít) Ii ds Ft ,
t

not even conditional on completion. Clearly this expectation will (among other parameters) depend on ¬µik , T , and Œªi . In the
model the state variable Kit governs how far the R&D investment project is from completion. The value of Kit is never directly
used as expected remaining R&D costs.
19Note that in the event that the two Ô¨Årms‚Äô estimated remaining R&D investment cost processes hit zero exactly at the same
instant in time or none of them hit zero before the patent expires at date T , Ô¨Årm one would be called the winning Ô¨Årm and Ô¨Årm
two would be called the losing Ô¨Årm. But as we will see in the derivation of the objective functions below in these two special
cases, there will be no diÔ¨Äerence between the winning Ô¨Årm‚Äôs and the losing Ô¨Årm‚Äôs objective functions. Hence, it does not really
matter which of the two we assign as the winning Ô¨Årm and which we assign as the losing Ô¨Årm in these two special cases.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

17

the two Ô¨Årms of all cash Ô¨Çows after that date can be derived as20

T
D2
Q
‚àír(s‚àít) D
V (Yt , t) ‚â° E
e
Œ†is ds Ft
t

=
=
(3)

a
‚àö EQ
2e b
T

a
‚àö
2e b

T

e‚àír(s‚àít) Ys ds Ft



t

e‚àír(s‚àít) E Q [Ys |Ft ]ds

t
T

a
= ‚àö
2e b

e‚àír(s‚àít) Yt e¬µy (s‚àít) ds

t

T
a
‚àö Yt e(r‚àí¬µy )t
e‚àí(r‚àí¬µy )s ds
2e b
t


a
‚àö Yt e(r‚àí¬µy )t e‚àí(r‚àí¬µy )t ‚àí e‚àí(r‚àí¬µy )T
=
2(r ‚àí ¬µy )e b


a
‚àö 1 ‚àí e‚àí(r‚àí¬µy )(T ‚àít) Yt ,
=
t ‚àà [œÑ , T ),
2(r ‚àí ¬µy )e b

=

where r is the riskless interest rate, which we for simplicity assume is constant. Note that the value will
only depend on the value of the state variable Y and the date t. The two state variables measuring the
estimated remaining R&D investment costs, K1 and K2 , are already zero so they are not relevant any more.
The superscript D2 indicates that this is the project value in the duopoly phase if there are still two projects
alive, i.e. if both projects have survived the catastrophic events and none of them have been abandoned for
economic reasons.
If one of the Ô¨Årms is hit by catastrophic events or if one of the Ô¨Årms abandons its R&D investment project
prior to the duopoly phase, the other Ô¨Årm would be able to earn a monopoly proÔ¨Åt even in the duopoly
phase. At any given date t in the duopoly phase, i.e. t ‚àà [œÑ , T ], the total value to the surviving Ô¨Årm of all
cash Ô¨Çows after that date can similarly be derived as
T

V D1 (Yt , t) ‚â° E Q
t

(4)
=

e‚àír(s‚àít) Œ†M
s ds Ft





a
‚àö
1 ‚àí e‚àí(r‚àí¬µy )(T ‚àít) Yt ,
(r ‚àí ¬µy ) 2be

t ‚àà [œÑ , T ).

The superscript D1 indicates that this is the surviving project value in the duopoly phase if only one of the
projects is alive.
If none of the two projects are alive in the duopoly phase, obviously no proÔ¨Åts will be made and the value
is therefore zero.
20Since we have already developed all our stochastic processes under an equivalent martingale measure, Q, the value of all

future proÔ¨Åts and costs can be calculated by just summing (integrating) all the expected cash Ô¨Çows (cash Ô¨Çow rates) discounted
using the riskless interest rate.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

18

In the monopoly phase, i.e. from date œÑ to date œÑ , the winning Ô¨Årm makes a monopoly proÔ¨Åt (if its project
is still alive) while the losing Ô¨Årm is (perhaps) still investing in R&D. For this period we will have to separate
the calculations of the values of the two Ô¨Årms. If the losing Ô¨Årm‚Äôs project is still alive, it is still investing
in R&D and, therefore, it is still exposed to catastrophic events. The conditional probability (under an
equivalent martingale measure, Q) that the losing Ô¨Årm is hit by catastrophic events during a period from
date t to date s in the monopoly phase, given that its project was alive at date t is 1 ‚àí e‚àíŒªl (s‚àít) . Similarly,
the conditional probability (under an equivalent martingale measure, Q) that it is not hit by catastrophic
events throughout the period from date t to date s in the monopoly phase, given that its project was alive at
date t is e‚àíŒªl (s‚àít) . The winning Ô¨Årm, on the other hand, is no longer exposed to catastrophic events since it
has already completed its R&D investment project at the entrance date into the monopoly phase. However,
the objective function of the losing Ô¨Årm depends on whether or not the winning Ô¨Årm‚Äôs project is alive at
the entrance date into the monopoly phase, since this determines whether the losing Ô¨Årm will be earning
a monopoly or a duopoly proÔ¨Åt when its R&D investment project is eventually completed. If the winning
Ô¨Årm‚Äôs project is still alive at the entrance date into the monopoly phase, then, at any given date t in the
monopoly phase, i.e. t ‚àà [œÑ , œÑ ), the total value to the losing Ô¨Årm (if its project is alive) of all cash Ô¨Çows after
that date can be derived as
ŒΩl

VlM 2l (Yt , Klt , t) ‚â° max E Q ‚àí
ŒΩl ‚ààS(F)

e‚àíŒªl (s‚àít) e‚àír(s‚àít) Il ds

t
‚àíŒªl (œÑ ‚àít) ‚àír(œÑ ‚àít)

+ 1{ŒΩl =œÑ } e
(5)

ŒΩl

= max E Q ‚àí
ŒΩl ‚ààS(F)

e


V

D2

(YœÑ , œÑ ) Ft

e‚àí(r+Œªl )(s‚àít) Il ds

t

+

a
‚àö e‚àí(r+Œªl )(œÑ ‚àít) √ó
2(r ‚àí ¬µy )e b



1 ‚àí e‚àí(r‚àí¬µy )(T ‚àíœÑ ) 1{ŒΩl =œÑ } YœÑ


Ft ,

t ‚àà [œÑ , œÑ ).

Note that the value will only depend on the value of the state variable Y , the estimated remaining R&D
investment costs for the losing Ô¨Årm, Kl , and the date t. The state variable measuring the estimated remaining
R&D investment costs for the winning Ô¨Årm, Kw , is already zero and therefore not relevant any more. The
superscript M 2l indicates that this is the losing Ô¨Årm‚Äôs value in the monopoly phase if the winning Ô¨Årm‚Äôs
project is still alive. Note the two terms in equation (5): the Ô¨Årst term is the losing Ô¨Årm‚Äôs R&D investment
costs in the monopoly phase after date t and until it is either hit by catastrophic events, it decides to
abandon its R&D investment project, or until its R&D investment project is completed; the second term is

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

19

the losing Ô¨Årm‚Äôs share of the duopoly proÔ¨Åt in the duopoly phase in the event that the losing Ô¨Årm is not hit
by catastrophic events in the period from date t and until the entrance date into the duopoly phase and it
does not decide to abandon its R&D investment project before completion. In equation (5) we use a so-called
indicator function of the form 1A , where A is some event. This function takes the value one if the event, A, is
true and zero otherwise. The value in equation (5) is the result of a maximization problem, since the losing
Ô¨Årm should decide at each instant in time whether to continue investing in R&D or to abandon the R&D
investment project. This decision must at each date be taken based on the available information, i.e. the past
and current values of the governing state variables. That is, the R&D investment/abandonment strategy
must be a stopping time related to the Ô¨Åltration F. We have indicated this restriction in equation (5) by
requiring ŒΩl to be a member of the set S(F). Denote the optimal R&D investment/abandonment strategy
for the problem in equation (5) as ŒΩlt2‚àó . Note that the optimal R&D investment/abandonment strategy
will depend on the valuation date t in the problem in equation (5), i.e., it is the (date t) optimal R&D
investment/abandonment strategy for the rest of the monopoly phase, given that the losing Ô¨Årm has not
yet abandoned its R&D investment project at date t. The superscript 2‚àó indicates that this is the (date t)
optimal R&D investment/abandonment strategy, given that the winning Ô¨Årm‚Äôs project is still alive at that
date.
Intuitively the optimal stopping time problem in equation (5) can be solved by dynamic programming.
The boundary condition is given by the value at the entrance date into the duopoly phase. That is,
(6)

VlM 2l (YœÑ , 0, œÑ ) = V D2 (YœÑ , œÑ ).

The optimal stopping time problem is solved by starting with the boundary condition and then going
backward in time in the usual dynamic programming fashion. That is, we solve for the value of the R&D
investment project at date t (in the monopoly phase) conditional on that we have already solved for the
value at any later date s. Let VlM 2l (Ys , Kls , s) denote the total value at date s in the monopoly phase to
the losing Ô¨Årm (if its project is still alive) of all cash Ô¨Çows after date s when it follows the optimal stopping
time rule. The value at date t to the losing Ô¨Årm, if it continues investing in its R&D investment project at
date t, can then (intuitively) be written as
(7)



VÃÇlM 2l (Yt , Klt , t) = E Q ‚àíe‚àí(r+Œªl )dt Il dt + e‚àí(r+Œªl )dt VlM 2l (Yt + dYt , Klt + dKlt , t + dt) Ft .

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

20

If VÃÇlM 2l (Yt , Klt , t) is positive, the losing Ô¨Årm should continue investing at date t, otherwise it should abandon
its R&D investment project. That is,
(8)



VlM 2l (Yt , Klt , t) = max VÃÇlM 2l (Yt , Klt , t), 0 .

To make this method rigorous in continuous time, we must derive a partial diÔ¨Äerential equation to solve for
VÃÇlM 2l , assuming that the Ô¨Årm continues investing, and at each instant in time check whether its value is
non-negative. As soon as it becomes negative, it is time to abandon the R&D investment project. This is
the same as the standard solution method normally applied to value an American option in a Black-Scholes
setting. Details can be found in Appendix A.
If the winning Ô¨Årm‚Äôs project is no longer alive at the entrance date into the monopoly phase,21 then at
any given date t in the monopoly phase, i.e. t ‚àà [œÑ , œÑ ), the total value to the losing Ô¨Årm (if its project is
alive) of all cash Ô¨Çows after that date can similarly be derived as
ŒΩl

VlM 1l (Yt , Klt , t) ‚â° max E Q ‚àí
ŒΩl ‚ààS(F)

e‚àí(Œªl +r)(s‚àít) Il ds

t

+ 1{ŒΩl =œÑ } e‚àí(Œªl +r)(œÑ ‚àít) V D1 (YœÑ , œÑ ) Ft
(9)

ŒΩl

= max E Q ‚àí
ŒΩl ‚ààS(F)



e‚àí(r+Œªl )(s‚àít) Il ds

t

+

a
‚àö
e‚àí(r+Œªl )(œÑ ‚àít) √ó
(r ‚àí ¬µy ) 2be


‚àí(r‚àí¬µy )(T ‚àíœÑ )

1‚àíe



1{ŒΩl =œÑ } YœÑ


Ft ,

t ‚àà [œÑ , œÑ ).

Here the superscript M 1l indicates that this is the losing Ô¨Årm‚Äôs project value in the monopoly phase if the winning Ô¨Årm‚Äôs project is no longer alive. In this case we denote the date t optimal R&D investment/abandonment
strategy for the problem in equation (9) as ŒΩlt1‚àó . Here the superscript 1‚àó indicates that this is the (date t)
optimal R&D investment/abandonment strategy, given that the winning Ô¨Årm‚Äôs project is no longer alive at
that date. This optimal stopping time problem can be solved in the same way as sketched in equation (7).
Details can be found in Appendix A.
In the valuation of the winning Ô¨Årm‚Äôs future cash Ô¨Çows we must take into account both the fact that the
losing Ô¨Årm is (perhaps) still investing in R&D and is therefore still exposed to catastrophic events, and the
fact that it will follow the just derived optimal R&D investment/abandonment strategy. At any given date

21Note again that the winning (losing) Ô¨Årm‚Äôs project refers to the project that would have been completed Ô¨Årst (last) if it is

neither abandoned for economic reasons nor hit by catastrophic events.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

21

t in the monopoly phase the winning Ô¨Årm (if its project is alive) can observe whether or not the losing Ô¨Årm‚Äôs
project is still alive. This observation is important for the valuation of the winning Ô¨Årm‚Äôs future cash Ô¨Çows
since this indicates whether there is still uncertainty about whether the losing Ô¨Årm will eventually complete
its R&D investment project or not. At any given date t in the monopoly phase, i.e. t ‚àà [œÑ , œÑ ), if the losing
Ô¨Årm‚Äôs project is still alive at that date, the total value to the winning Ô¨Årm of all cash Ô¨Çows after that date
can be derived as,
VwM 2w (Yt , Klt , t) ‚â° E Q

œÑ
t

+

‚àíŒªl (œÑ ‚àít) ‚àír(œÑ ‚àít) D2
2‚àó =œÑ } e
e‚àír(s‚àít) Œ†M
e
V (YœÑ , œÑ )
s ds + 1{ŒΩlt





1 ‚àí e‚àíŒªl (œÑ ‚àít) 1{ŒΩlt2‚àó =œÑ } + 1{ŒΩlt2‚àó <œÑ } e‚àír(œÑ ‚àít) V D1 (YœÑ , œÑ ) Ft

a
= EQ ‚àö
2be

œÑ

e‚àír(s‚àít) Ys ds

t



a
‚àö 1 ‚àí e‚àí(r‚àí¬µy )(T ‚àíœÑ ) 1{ŒΩlt2‚àó =œÑ } YœÑ
2(r ‚àí ¬µy )e b



+ 1 ‚àí e‚àíŒªl (œÑ ‚àít) 1{ŒΩlt2‚àó =œÑ } + 1{ŒΩlt2‚àó <œÑ } e‚àír(œÑ ‚àít) √ó
+ e‚àí(r+Œªl )(œÑ ‚àít)

(10)




a
‚àí(r‚àí¬µy )(T ‚àíœÑ )
‚àö
1‚àíe
YœÑ Ft
(r ‚àí ¬µy ) 2be

œÑ
a
=‚àö
EQ
e‚àír(s‚àít) Ys ds Ft
2be
t


a
‚àö E Q e‚àí(r+Œªl )(œÑ ‚àít) 1 ‚àí e‚àí(r‚àí¬µy )(T ‚àíœÑ ) 1{ŒΩlt2‚àó =œÑ } YœÑ
+
2(r ‚àí ¬µy )e b
+



a
‚àö
E Q e‚àír(œÑ ‚àít) 1 ‚àí e‚àí(r‚àí¬µy )(T ‚àíœÑ ) √ó
(r ‚àí ¬µy ) 2be



1 ‚àí e‚àíŒªl (œÑ ‚àít) 1{ŒΩlt2‚àó =œÑ } + 1{ŒΩlt2‚àó <œÑ } YœÑ


Ft


Ft ,

t ‚àà [œÑ , œÑ ).

The superscript M 2w indicates that this is the winning Ô¨Årm‚Äôs project value in the monopoly phase if the
losing Ô¨Årm‚Äôs project is still alive. Note the three terms in equation (10): the Ô¨Årst term is the winning Ô¨Årm‚Äôs
monopoly proÔ¨Åt from date t and until the end of the monopoly phase; the second term is the winning Ô¨Årm‚Äôs
share of the duopoly proÔ¨Åt in the duopoly phase in the event that the losing Ô¨Årm is not hit by catastrophic
events in the period from date t and until the entrance date into the duopoly phase and the losing Ô¨Årm
does not abandon its R&D investment project before completion; Ô¨Ånally the third term is the winning Ô¨Årm‚Äôs
monopoly proÔ¨Åt in the duopoly phase in the event that the losing Ô¨Årm is either hit by catastrophic events
before the entrance date into the duopoly phase or the losing Ô¨Årm Ô¨Ånds it optimal to abandon its R&D
investment project before completion.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

22

Finally, if the losing Ô¨Årm‚Äôs project is no longer alive, the winning Ô¨Årm will be able to make a monopoly
proÔ¨Åt until its patent expires. Hence, we can value its proÔ¨Åt in the same way as in the duopoly phase. That
is, at any given date t in the monopoly phase, i.e. t ‚àà [œÑ , œÑ ), if the losing Ô¨Årm‚Äôs project is no longer alive at
that date, the total value to the winning Ô¨Årm of all cash Ô¨Çows after that date can be derived as,
(11)

V M 1w (Yt , t) ‚â° V D1 (Yt , t) =



a
‚àö
1 ‚àí e‚àí(r‚àí¬µy )(T ‚àít) Yt ,
(r ‚àí ¬µy ) 2be

t ‚àà [œÑ , œÑ ),

even though, strictly speaking, V D1 is not deÔ¨Åned to be used in the monopoly phase. Note that the value
will only depend on the value of the state variable Y , and the date t. The state variable measuring the
estimated remaining R&D investment costs for the losing Ô¨Årm, Kl , is no longer relevant since that Ô¨Årm has
either been hit by catastrophic events or has abandoned its R&D investment project before completion. The
superscript M 1w indicates that this is the winning Ô¨Årm‚Äôs project value in the monopoly phase if the losing
Ô¨Årm‚Äôs project is no longer alive.
In the competitive R&D phase before any of the two drugs are marketed, i.e. from date zero to date œÑ , the
two Ô¨Årms are competing to market their drug before the competitor markets its drug. Therefore, the actual
R&D investment/abandonment decision itself is somewhat trickier in this phase. In the monopoly phase
there was no element of competitive interaction between the two Ô¨Årms in the R&D investment decision itself:
the losing Ô¨Årm simply considers, given that the winning Ô¨Årm is already making a monopoly (production)
proÔ¨Åt in the monopoly phase, whether it is more proÔ¨Åtable to continue investing in R&D or whether it is
more proÔ¨Åtable to abandon its R&D investment project. In the competitive R&D phase, when both Ô¨Årms
are still investing in R&D, there is a competitive interaction element to the R&D investment/abandonment
strategy. There is a clear advantage to the Ô¨Årm which markets its drug before its competitor. Moreover,
it may very well be the case that the value to one of the Ô¨Årms of all future cash Ô¨Çows is negative, if the
other Ô¨Årm continues investing in R&D, but positive if the other Ô¨Årm abandons its R&D investment project.
Hence, the R&D investment/abandonment strategy may not only depend on the valuation of the Ô¨Årm‚Äôs own
R&D investment project. That is, we will have to use the same kind of reasoning in order to Ô¨Ånd the optimal
R&D investment/abandonment strategies for both of the Ô¨Årms as we did in the derivation of the duopoly
production rates, i.e., a Cournot-Nash type equilibrium. Therefore, we must investigate at any given date t
the two Ô¨Årms‚Äô response functions in terms of their date t optimal R&D investment/abandonment decision, as
a reaction to their competitor‚Äôs given date t R&D investment/abandonment decision. To solve that problem
we Ô¨Årst need to know the date t value of the project as well as the optimal R&D investment strategy if the
other Ô¨Årm is hit by catastrophic events or if it abandons its R&D investment project for economic reasons.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

23

This is a standard optimal stopping time problem that can be solved by the same methods as applied for the
losing Ô¨Årm in the monopoly phase. That is, at any given date t in the competitive R&D phase, i.e. t ‚àà [0, œÑ ),
if the other Ô¨Årm‚Äôs project is no longer alive, the total value to Ô¨Årm i of all cash Ô¨Çows after that date can be
derived as,
ViR&D1 (Yt , Kit , t) ‚â° max E Q ‚àí
(12)

ŒΩi ‚ààS(F)

ŒΩi

e‚àí(r+Œªi )(s‚àít) Ii ds

t


+ 1{ŒΩi =œÑi } e‚àí(r+Œªi )(œÑi ‚àít) V M 1w (YœÑi , œÑi ) Ft ,

t ‚àà [0, œÑ ).

In equation (12) we have exploited the fact that V D1 and V M 1w are identical, even though, strictly speaking,
they are not deÔ¨Åned on the same time intervals, cf. equation (11). Note that the value will only depend on
the value of the state variable Y , the estimated remaining R&D investment costs for the Ô¨Årm itself, Ki , and
the date t. The state variables measuring the estimated remaining R&D investment costs for the competing
Ô¨Årm, Kj , for j = 3 ‚àí i, is no longer relevant since that Ô¨Årm has either been hit by catastrophic events or has
abandoned its R&D investment project before completion. The superscript R&D1 indicates that this is the
project value in the competitive R&D phase if the other Ô¨Årm‚Äôs project is no longer alive. Note the two terms
in equation (12): the Ô¨Årst term is Ô¨Årm i‚Äôs R&D investment costs from date t and until it is either hit by
catastrophic events, it decides to abandon its R&D investment project, or until its R&D investment project
is completed; the second term is Ô¨Årm i‚Äôs monopoly proÔ¨Åt in the event that its project is completed. In this
case we denote the date t optimal R&D investment/abandonment strategy for the problem in equation (12)
1‚àó
. Again the superscript 1‚àó indicates that this is the (date t) optimal R&D investment/abandonment
as ŒΩit

strategy, given that the other Ô¨Årm‚Äôs project is no longer alive at that date. This optimal stopping time
problem can be solved in the same way as sketched in equation (7). Details can be found in Appendix A.
Now that we know the date t value of Ô¨Årm i‚Äôs R&D investment project if the other Ô¨Årm decides to abandon
its R&D investment project, we need to derive the date t value of Ô¨Årm i‚Äôs R&D investment project if the
other Ô¨Årm continues investing in its R&D investment project in order to Ô¨Ånd the best response function.
In order to derive the date t value of Ô¨Årm i‚Äôs R&D investment project if the other Ô¨Årm continues investing
in its R&D investment project, we must take into account both the fact that both Ô¨Årms are exposed to
catastrophic events and the fact that both Ô¨Årms follow R&D investment strategies that are Cournot-Nash
equilibria at any later date s ‚â• t in the competitive R&D phase. Therefore, in the case where both Ô¨Årms are
still investing in their R&D investment projects, we cannot just write the objective function of Ô¨Årm i at date
t as a simple optimal stopping time problem as we have done in the monopoly phase for the losing Ô¨Årm and
in the competitive R&D phase when there is only one project left. Because of the competitive interactions

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

24

we are only able to derive the objective function as a solution to a dynamic programming problem. If both
projects are alive in the competitive R&D phase, the boundary conditions for the project values are given
by the value at the entrance date into the monopoly phase. That is,22
VwR&D2 (YœÑ , KlœÑ , 0, œÑ ) = VwM 2w (YœÑ , KlœÑ , œÑ )

(13)

and
VlR&D2 (YœÑ , KlœÑ , 0, œÑ ) = VlM 2l (YœÑ , KlœÑ , œÑ ).

(14)

The valuation problem in the competitive R&D phase is then solved by going backward in time in the usual
dynamic programming fashion. That is, we solve for the value of the R&D investment project at date t (in
the competitive R&D phase) conditional on that we have already solved for the value at any later date s.
Let ViR&D2 (Ys , K1s , K2s , s) denote the total value to Ô¨Årm i at date s of all cash Ô¨Çows after date s in the
competitive R&D phase if both projects are still alive and both Ô¨Årms follow R&D investment strategies that
are Cournot-Nash equilibria at any later date u ‚â• s in the competitive R&D phase. From equation (12) we
have, in addition, derived the total value at date s in the competitive R&D phase to Ô¨Årm i of all cash Ô¨Çows
after date s when it follows the optimal stopping time rule in the case where the other Ô¨Årm abandons its R&D
investment project. This value is denoted ViR&D1 (Ys , Kis , s). The total value at date t in the competitive
R&D phase to Ô¨Årm i (if its project is still alive) of all cash Ô¨Çows after date t, if both Ô¨Årms continue investing
in their R&D investment projects at date t, can then (intuitively) be written as
VÃÇiR&D2 (Yt , K1t , K2t , t) = E Q ‚àíe‚àí(r+Œªi )dt Ii dt
+ e‚àí(r+Œªi +Œªj )dt ViR&D2 (Yt + dYt , K1t + dK1t , K2t + dK2t , t + dt)
(15)



+ e‚àí(r+Œªi )dt 1 ‚àí e‚àíŒªj dt √ó

ViR&D1 (Yt + dYt , Kit + dKit , t + dt) Ft .

The superscript R&D2 indicates that this is the Ô¨Årm‚Äôs value in the competitive R&D phase if the other
Ô¨Årm‚Äôs project is still alive.

22In this derivation of the boundary conditions we have implicitly assumed that Ô¨Årm two is the winning Ô¨Årm and that Ô¨Årm one

is the losing Ô¨Årm. If the opposite situation is the case, then KlœÑ and zero should be interchanged in the arguments of both
V R&D2 s on the left hand sides of the equations.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

25

Firm two

Firm one

Continues investing

Abandons

Continues investing

VÃÇ1R&D2 (Yt , K1t , K2t , t), VÃÇ2R&D2 (Yt , K1t , K2t , t)

V1R&D1 (Yt , K1t , t), 0

Abandons

0, V2R&D1 (Yt , K2t , t)

0, 0

Table 1. Normal form representation of the R&D investment game with competitive interactions between the two Ô¨Årms at date t in the competitive R&D phase. The table contains
the date t value to each of the two duopolists of all future cash Ô¨Çows after that date (Ô¨Årm
one‚Äôs value before the comma and Ô¨Årm two‚Äôs value after the comma) given that both Ô¨Årms
follow the decisions indicated in the margin of the box at date t and that both Ô¨Årms follow
R&D investment strategies that are Cournot-Nash equilibria at any later date s ‚â• t in the
competitive R&D phase.

To Ô¨Ånd the Cournot-Nash type equilibrium R&D investment/abandonment decisions at date t for the two
Ô¨Årms in the competitive R&D phase, we will have to consider the game in Table 1. Table 1 contains the date t
value to each of the two duopolists of all future cash Ô¨Çows after that date (Ô¨Årm one‚Äôs value before the comma
and Ô¨Årm two‚Äôs value after the comma) given that both Ô¨Årms follow the decisions indicated in the margin of
the box at date t and that both Ô¨Årms follow R&D investment strategies that are Cournot-Nash equilibria at
any later date s ‚â• t in the competitive R&D phase. Take, e.g., the upper right corner of the box in Table 1.
The two numbers, V1R&D1 (Yt , K1t , t), 0, indicate that if Ô¨Årm one continues investing in its R&D investment
project and Ô¨Årm two abandons its R&D investment project, then the value of all future cash Ô¨Çows to Ô¨Årm one
would be V1R&D1 (Yt , K1t , t), whereas the value of all future cash Ô¨Çows to Ô¨Årm two would be zero. Naturally,
VÃÇiR&D2 (Yt , K1t , K2t , t) < ViR&D1 (Yt , Kit , t), for both i = 1 and i = 2, i.e., the value to Ô¨Årm i of all future
cash Ô¨Çows if it continues investing in R&D is lower if the other Ô¨Årm also continues investing in R&D than if
the other Ô¨Årm abandons its R&D investment project, ceteris paribus. If VÃÇiR&D2 (Yt , K1t , K2t , t) ‚â• 0, for both
i = 1 and i = 2, there is a unique Nash equilibrium in simple strategies. This equilibrium is that both Ô¨Årms
continue investing. If, for one i, VÃÇiR&D2 (Yt , K1t , K2t , t) ‚â• 0 and VÃÇjR&D2 (Yt , K1t , K2t , t) < 0, for j = 3 ‚àí i,
then the unique Nash equilibrium in simple strategies is that Ô¨Årm i continues investing in R&D, whereas
Ô¨Årm j = 3 ‚àí i abandons its R&D investment project. If ViR&D1 (Yt , Kit , t) < 0, for both i = 1 and i = 2,
then the unique Nash equilibrium in simple strategies is that both Ô¨Årms abandon their R&D investment
projects. If, for one i, ViR&D1 (Yt , Kit , t) ‚â• 0 and VjR&D1 (Yt , Kjt , t) < 0, for j = 3 ‚àí i, then the unique Nash
equilibrium in simple strategies is that Ô¨Årm i continues investing in R&D, whereas Ô¨Årm j = 3 ‚àí i abandons
its R&D investment project. Finally, if ViR&D1 (Yt , Kit , t) ‚â• 0 and VÃÇiR&D2 (Yt , K1t , K2t , t) < 0, for both i = 1
and i = 2, then there are multiple Nash equilibria in simple strategies. It is a Nash equilibrium in simple
strategies that one of the Ô¨Årms continues investing in R&D and the other abandons its R&D investment

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

26

project. The question is how the two Ô¨Årms should select a rule for which of the two Ô¨Årms should continue
investing in R&D and which of them should abandon its R&D investment project. Any rule that given
the information set available to the two Ô¨Årms unambiguously selects which of the two Ô¨Årms should continue
investing in R&D and which of them should abandon its R&D investment project is a Nash equilibrium. In
our numerical solution procedure presented in Section 3 we have implemented the rule that the Ô¨Årm with
the highest value of continuing investing in R&D, given that the other Ô¨Årm abandons its R&D investment
project, continues investing in R&D, and the other Ô¨Årm abandons its R&D investment project. In the
zero-probability event that both Ô¨Årms have identical values of continuing investing in R&D, given that the
other Ô¨Årm abandons its R&D investment project, we say that Ô¨Årm two continues investing in R&D and
Ô¨Årm one abandons its R&D investment project.23 That is, we have implemented the rule that it is Ô¨Årm
one which continues investing in R&D and Ô¨Årm two which abandons its R&D investment project if and
only if V1R&D1 (Yt , K1t , t) > V2R&D1 (Yt , K2t , t). This Nash equilibrium among all Nash equilibria is the one
that gives the highest ex ante values of the two Ô¨Årms‚Äô projects and therefore it should be the one Nash
equilibrium that both Ô¨Årms would prefer to play. One economic motivation for this reÔ¨Ånement criterion is
a story related to mutual threads of war of attrition.24 First of all we can think of the two Ô¨Årms as the
two opponents of a potential war of attrition. Firm i‚Äôs gain from winning this war of attrition by forcing
Ô¨Årm j = 3 ‚àí i to abandon its R&D investment project at date t is ViR&D1 (Yt , Kit , t). Both Ô¨Årms know their
own and their opponent‚Äôs potential gains from winning this war of attrition. Since the value of losing the
potential war of attrition is zero, ViR&D1 (Yt , Kit , t) can also be interpreted as the maximum amount that
Ô¨Årm i would be willing to spend in order to win this war of attrition. Faced with these facts we Ô¨Ånd it
plausible that the Ô¨Årm with the lowest value of V R&D1 voluntarily abandons its R&D investment project
without even starting the war of attrition. This implies that the Ô¨Årm with the highest value of V R&D1
can continue its R&D investment project as a monopolist without having to spend any money to win the
war of attrition. It is also possible to think about this reÔ¨Ånement in terms of mergers and acquisitions. In
these cases the equilibrium outcome would be the same, i.e. the Ô¨Årm with the highest value of V R&D1 will
continue its R&D investment project and the other Ô¨Årm would abandon its R&D project, but typically a
Nash bargaining game would be involved and there would be a wealth transfer from the Ô¨Årm with the highest
value of V R&D1 to the Ô¨Årm with the lowest value of V R&D1 . In this case there could also be an increase in
23Since we assume that both projects are identical at date zero, i.e. we are working with symmetric Ô¨Årms, this event happens

with probability one at date zero when the projects are marginal. This means that whenever it is not optimal for both duopolists
to initiate their R&D investment projects at date zero, only Ô¨Årm two would initiate its R&D investment project and we will de
facto have a monopoly situation.
24Other articles that consider wars of attrition in duopoly situations are Ghemawat and NalebuÔ¨Ä (1985), Fudenberg and Tirole
(1986), and Lambrecht (2001).

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

27

value to above the highest value of V R&D1 if the two R&D investment projects can be combined in some way
as a result of a merger or an acquisition. Finally, there is also a Nash equilibrium in mixed strategies. For
comparison we have also implemented this rule in our numerical solution procedure presented in Section 3.
This equilibrium is that Ô¨Årm i = 3‚àíj continues investing with probability
and abandons with probability 1 ‚àí

VjR&D1 (Yt ,Kjt ,t)

VjR&D1 (Yt ,Kjt ,t)‚àíVÃÇjR&D2 (Yt ,K1t ,K2t ,t)

VjR&D1 (Yt ,Kjt ,t)
R&D1
Vj
(Yt ,Kjt ,t)‚àíVÃÇjR&D2 (Yt ,K1t ,K2t ,t)

, for both Ô¨Årms i = 1 and i = 2. Note

that ViR&D1 (Yt , Kit , t) ‚â• 0 and VÃÇiR&D2 (Yt , K1t , K2t , t) < 0, for both i = 1 and i = 2, such that the
probabilities for continuing investing are positive and strictly less than one. This alternative equilibrium,
while theoretically appealing in the sense that it provides the same value (namely zero) to both projects at
date t, does not provide the highest ex-ante value for the projects. Hence, we have found the Cournot-Nash
type equilibrium investment decisions for date t. The date t values for each of the two projects corresponding
to the outcome of this Cournot-Nash type investment game can then be assigned to V1R&D2 and V2R&D2 ,
cf. equations (16) and (17) in Appendix B. This last step replaces equation (8) in the optimal stopping
time problem. To make this method rigorous in continuous time we must derive two partial diÔ¨Äerential
equations to solve for VÃÇ1R&D2 and VÃÇ2R&D2 assuming that both Ô¨Årms continue investing, and at each instant
in time check that it is a Nash equilibrium for both Ô¨Årms to continue investing. As soon as one of the other
three outcomes of the game becomes a Nash equilibrium the competitive interactions come to an end and
the corresponding values from equation (12) can be substituted in as a boundary condition. Details can be
found in Appendix B.
The way to solve for the date zero Cournot-Nash type equilibrium R&D investment/abandonment strategies for the two Ô¨Årms is to successively solve for Nash equilibria in the game in Table 1 at each instant in time,
starting with equations (13) and (14) at the entrance date into the monopoly phase and going backwards in
time using equation (15) until date zero.
3. Numerical Solution Procedure
We solve the model numerically by applying a variation of the LongstaÔ¨Ä-Schwartz method (LongstaÔ¨Ä and
Schwartz 2001). This is done by Ô¨Årst simulating 100,000 discretizised25 sample paths of the three governing
state variables Y , K1 , and K2 . It is then easy to determine the two stopping times œÑ and œÑ for each sample
path, cf. Figure 3. The value of all future proÔ¨Åts to each of the two Ô¨Årms can easily be calculated at date œÑ by
equations (3) and (4) in both the case where the Ô¨Årm will be the only one on the market, i.e. a monopolist, and
in the case where the Ô¨Årms will be sharing the market, i.e. duopolists. The reason that we have to calculate
25In our implementation we have used a discretization based on three-month intervals. That is, we have separated the twenty-

year time period, [0, T ], into 80 quarters.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

28

both proÔ¨Åt values is that we do not know if and when one of the two Ô¨Årms will abandon its R&D investment
project or if and when it may be hit by catastrophic events. The losing Ô¨Årm‚Äôs value in the monopoly phase
is, however, a little bit more problematic in that it involves the R&D investment/abandonment decision,
cf. equations (5) and (9). The value of the losing Ô¨Årm, at any given date in the monopoly phase, of all
future cash Ô¨Çows, if the Ô¨Årm continues investing in R&D, can be approximated by the following backward
procedure similar in spirit to equation (7): regress the continuation value along each of the sample paths
which are in the monopoly phase at the same date on a speciÔ¨Åc function of the current values along the
corresponding sample paths of the two governing state variables, Kl and Y . The regression coeÔ¨Écients from
this regression is used to approximate the value, at this date in the monopoly phase, of all future cash Ô¨Çows,
if the Ô¨Årm continues investing in R&D, simply by applying the regression to the current values of the two
governing state variables.26 If the value of continuing investing in R&D is greater than the costs of investing
in R&D for another quarter, the Ô¨Årm should continue investing in R&D, otherwise it should abandon its
R&D investment project. This procedure gives us the value of all future cash Ô¨Çows for the losing Ô¨Årm back
to date œÑ as well as the Ô¨Årm‚Äôs R&D investment/abandonment decisions along each sample path for each
quarter in the monopoly phase both in the case where both projects are alive and in the case where there
is only one project alive. With the losing Ô¨Årm‚Äôs R&D investment/abandonment decisions along each sample
path for each quarter in the monopoly phase it is quite easy to calculate the winning Ô¨Årm‚Äôs value of all future
proÔ¨Åts at date œÑ by equations (10) and (11).
In the competitive R&D phase, the same method is applied to approximate the value of all future cash
Ô¨Çows, given the current value of the (now three) governing state variables, K1 , K2 and Y , cf. equation (15).
However, as we saw in Section 2 the actual R&D investment/abandonment decision is somewhat more tricky
in this situation as we, for each quarter, have to go through the game in Table 1 to Ô¨Ånd the Nash equilibrium
R&D investment/abandonment decisions based on the values from equations (12) and (15). Note that in
the case where we allow for mixed strategies the investment/abandonment decision is not just an eitheror decision (either the Ô¨Årm continues investing in its R&D project, or it abandons its project), the mixed
strategy is implemented as a probability of continuing to invest.

26The LongstaÔ¨Ä-Schwartz method exploits the fact that the continuation value, i.e. the date t value of all future cash Ô¨Çows from

the R&D investment project if the Ô¨Årm continues investing in R&D (including the option to abandon later on), is simply the
date t conditional expectation of the value of the true future cash Ô¨Çows from the R&D investment project under an equivalent
martingale measure, Q. Since the current date t value of the two governing state variables is a suÔ¨Écient statistic of all date t
information, it follows that the conditional expectation under Q is some (unknown) function of the current realized values of
the two governing state variables. It is this unknown function that we try to approximate/estimate at each instant in time.
This is done by estimating ten coeÔ¨Écients in a cubic polynomial parameterization of the function.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

29

When this backward procedure is carried out starting from date T = 20 and quarter by quarter going
backwards through the duopoly phase, the monopoly phase, and the competitive R&D phase back to date
zero, all the R&D investment/abandonment decisions (possible as mixed strategies) for the two Ô¨Årms have
been determined for each quarter and for each of the 100,000 sample paths, both in the case where there are
still two projects alive and in the case where there is only one project alive. The actual values of all future
cash Ô¨Çows from continuing the R&D investment project which are the results of the regressions that has been
run are not used in the computation of the value of the projects, only the R&D investment/abandonment
decisions they have caused are used.
In order to value the R&D investment projects for the two Ô¨Årms at date zero we implement a forward
procedure that Ô¨Ånds the value by evaluating the proÔ¨Åt along each sample path taking into account the R&D
investment/abandonment decisions (possible as mixed strategies) derived by the backward procedure and
averaging over all the sample paths.

4. Numerical Results
In this section we provide a numerical illustration of the model. Since we solve the problem using numerical
simulations, we are able to characterize the solution in great detail. We Ô¨Årst develop a base case and then
we perform sensitivity analysis with respect to some of the key parameters of the model. We emphasize the
diÔ¨Äerences between competitive (duopoly) and monopoly solutions to the R&D investment project. We have
two diÔ¨Äerent competitive solutions: one using the war of attrition reÔ¨Ånement and one using mixed strategies
and also two diÔ¨Äerent monopoly solutions: one where the monopolist only has access to project one and one
where the monopolist has access to both projects.
Table 2 contains the data for the base case. The inverse demand function parameters are the same as
the ones used to construct Figure 2. Note that parameter a is a measure of the size of the market for the
product and that parameter b is a measure of the depth of the market, i.e., a measure for how much the
price would change for a given change in supplied quantity. The R&D investment cost parameters are the
ones used to construct the sample paths in Figure 3. The other parameters are chosen to represent a typical
drug development project (Schwartz 2001).
The results of the numerical simulations for the base case are shown in Table 3. As expected the value of
the R&D investment project in the monopoly situation is higher than the sum of the values of the two R&D
investment projects in the duopoly situation. The monopolist not only optimizes its production rate after
completion of the R&D investment project in order to maximize its own per period production proÔ¨Åts, but it

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

30

Inverse demand function
First parameter
Second parameter

a
b

15
0.1

Drift parameter

¬µy

0

DiÔ¨Äusion parameter
Initial value

œÉy
Y0

20%
1

Demand shocks

Estimated remaining R&D investment costs for Ô¨Årm one‚Äôs project
Initial value
K10
100
Investment rate
DiÔ¨Äusion parameter of technical shocks

I1
Œ≥1

10
20%

Drift parameter of input cost shocks
DiÔ¨Äusion parameter of input cost shocks

¬µ1k
œÉ1k

0
10%

Estimated remaining R&D investment costs for Ô¨Årm two‚Äôs project
Initial value
K20
100
Investment rate
DiÔ¨Äusion parameter of technical shocks

I2
Œ≥2

10
20%

Drift parameter of input cost shocks
DiÔ¨Äusion parameter of input cost shocks

¬µ2k
œÉ2k

0
10%

Other parameters
Intensity of catastrophic events for Ô¨Årm one

Œª1

0.07

Intensity of catastrophic events for Ô¨Årm two
Correlation between demand shocks and input cost shocks

Œª2
œÅyk

0.07
‚Äì0.1

r
T

5%
20

Numerical procedure parameters
Number of simulated paths

N

100,000

Duration of each time step

‚àÜt

0.25

Riskless interest rate
Duration of the patent period

Table 2. Base case parameter values.

also uses an optimal R&D investment/abandonment strategy during the period of R&D investments without
having to consider competitive interactions. In the base case it turns out not to be optimal to initiate a
backup project.27 Hence, the results are identical for the monopolist who has access only to project one and
for the monopolist who has access to both projects. Note that the present value of the revenues generated
during the production period is 27% higher in the duopoly situation than in the monopoly situation even
though on average the price per unit sold is lower in the duopoly situation than in the monopoly situation.
27

In fact, it turns out only to be optimal for a monopolist to initiate the backup project for very proÔ¨Åtable R&D investment
projects. In our numerical examples this only happens when a = 17.5 or higher, cf. Figure 4 below.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

Value of R&D investment project(s)
Present value of revenues

Duopoly situation

Duopoly situation

with war of attrition

with mixed strategies

31

Monopoly situation

4.9

4.9

10.0

63.7

63.6

50.3

Present value of R&D investment costs

58.8

58.7

40.4

Total number of units produced

11.6

11.5

8.5

Present value of revenue per unit produced

5.5

5.5

5.9

Present value of R&D investment costs per unit prod.

5.1

5.1

4.7

Probability of catastrophic events for each Ô¨Årm

24.4%

24.3%

33.5%

Probability of economic abandonment for each Ô¨Årm

50.8%

51.0%

32.3%

Total probability of not completing for each Ô¨Årm

75.2%

75.3%

65.7%

Probability that at least one Ô¨Årm completes

43.4%

43.3%

34.3%

5.6%

5.6%

Probability that both Ô¨Årms complete

n/a

Table 3. Results of base case analysis using the base case parameter values from Table 2.

This is due to the fact that, on average, the total number of units produced is 36% higher in the duopoly
situation than in the monopoly situation. There are three reasons, all working in the same direction, for this
higher production in the duopoly situation. Firstly, there is a higher probability that a product is developed
in the duopoly situation than in the monopoly situation since (i) catastrophic events are diversiÔ¨Åed over
the two duopolists and (ii) the R&D investment costs for the winning duopoly Ô¨Årm are on average smaller
than the R&D investment costs for the monopoly Ô¨Årm because the winning duopoly Ô¨Årm typically has the
estimated remaining R&D investment cost process which hits zero Ô¨Årst. Secondly, on average the time to
completion for the Ô¨Årst product is shorter in the duopoly situation than in the monopoly situation so there
is a longer time period to produce before the patents expire. Thirdly, in those cases where both duopolists
complete their R&D investment projects, the production rate is higher after the second Ô¨Årm completes its
R&D investment project (see Ô¨Ågure 2). The Ô¨Çip side of the beneÔ¨Åts of having more units produced in the
duopoly situation is that the total present value of the R&D investment costs is higher in the duopoly
situation than in the monopoly situation. Even on a per unit basis the present value of the R&D investment
costs is higher in the duopoly situation than in the monopoly situation, since there is a duplication of the
R&D investment costs. The results are practically identical for the two diÔ¨Äerent implemented reÔ¨Ånements
of the duopoly situation. Practically it does not matter for this case whether the duopolists play mixed
strategies or play a war of attrition game. Therefore, in the following we will only report on the duopoly
results with war of attrition reÔ¨Ånements. We will, however, comment on the results related to duopoly
with mixed strategies when there are signiÔ¨Åcant diÔ¨Äerences between the results when using war of attrition
reÔ¨Ånement and mixed strategies.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

32

Now let us turn to the analysis of the probabilities of abandonment.28 The probability of abandonment of
the R&D investment project because it is no longer proÔ¨Åtable to continue investing (economic abandonment)
for each of the two duopolists is much larger (50.8‚Äì51.0%) than it is for the monopolist (32.3%), since the
expected future cash Ô¨Çows to each of the two duopolists are smaller. A consequence of this is that on
average the life time of an R&D investment project initiated by a duopolist is shorter than the life time of
an R&D investment project initiated by a monopolist, and therefore the probability of catastrophic events is
smaller for a given R&D investment project if it is initiated by a duopolist (24.3‚Äì24.4%) than if it is initiated
by a monopolist (33.5%). The outcome of these two opposing eÔ¨Äects is that, on a per project basis, the
probability of completion of the R&D investment project is higher if the R&D investment project is initiated
by a monopolist than if it is initiated by a duopolist. If we take into account that there are two duopolists,
each with an R&D investment project; however, the probability that at least one of the two duopolists will
complete is higher (43.3‚Äì43.4%) than the probability that the monopolist will complete (34.3%). Finally, in
our base case, the probability that both duopolists complete is only 5.6%. That is, the conditional probability
that the second duopolist completes, conditional on the Ô¨Årst completing, is only 22.3‚Äì22.6%, which is lower
than the unconditional probability that a given duopolist will complete (24.7‚Äì24.8%).
In summary, if we only take into account the value of the R&D investment projects, the monopoly
situation is the superior alternative for society. But, if society‚Äôs objective criteria include the number of
units produced, the price per unit produced, the time to complete the R&D investment project, and the
probability of successful completion, the duopoly situation may very well be the superior alternative. Note
that these beneÔ¨Åts of the duopoly situation came about not only because of the lower price charged when
both duopolists are producing, but also because of the fact that the chance of completion is higher and the
expected time to completion of the Ô¨Årst R&D investment project is shorter. These results are robust to
most of the numerical simulations we have performed. Only when the R&D investment projects are very
marginal will monopoly induce higher probability of successful completion and thereby a higher number of
units produced than duopoly with mixed strategies. If the duopolists are playing war of attrition, the results
are identical to the monopoly case since the R&D investment projects are so marginal that one of the two
duopolists abandon at date zero.
To get to a deeper understanding of the insights of the model, we now perturb some of the key parameters
of the model and analyze their impact, for both the duopoly and monopoly situations, on valuation, number
of units produced, and probabilities of completion. We Ô¨Årst analyze the sensitivity to the size of the market.
28

Note that these are risk neutral probabilities since we have only developed the stochastic processes under an equivalent
martingale measure, Q.

25.0

27.5

12.0

12.5

13.0

13.5

14.0

14.5

15.5

16.0

16.5

Parameter a

15.0

17.0

17.5

18.0

18.5

19.0

19.5

20.0

0.50

13.5

14.0

14.5

15.0

15.5

16.0

16.5

17.0

17.5

18.0

18.5

19.0

19.5

20.0

12.5

13.0

13.5

14.0

14.5

15.5

16.0

16.5

Parameter a

15.0

17.0

17.5

18.0

18.5

19.0

19.5

20.0

12.5

13.0

13.5

14.0

14.5

15.5

16.0

16.5

Parameter a

15.0

17.0

17.5

18.0

18.5

19.0

19.5

20.0

(d) Present value of costs (solid line) and revenues (dasheddotted line) in the monopoly situation and present value of costs
(dashed line) and revenues (dotted line) in the duopoly situation
per unit produced as a function of market size, a.

12.0

Figure 4. Sensitivity analysis between duopoly with war of attrition reÔ¨Ånement and monopoly with respect to the market size, a.

(c) Probabilities of completion in the monopoly situation (solid
line), and probabilities that at least one of the duopolists completes (dashed line), and that both of the duopolists (dotted
line) complete in the duopoly situation as a function of market
size, a.

Parameter a

4.50
11.5

13.0

0.00
11.5

5.00

5.25

5.50

5.75

6.00

6.25

6.50

4.75

12.5

6.75

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

Probabilities of completion

7.00

7.25

0.55

7.50

Values per unit produced

12.0

(b) Units produced in the monopoly (solid line) and the duopoly
(dashed line) situations as a function of market size, a.

11.5

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

8.0

9.0

10.0

11.0

12.0

0.60

12.0

13.0

14.0

15.0

16.0

0.65

(a) Values of R&D investment projects in the monopoly (solid
line) and the duopoly (dashed line) situations as a function of
market size, a.

0.0
11.5

2.5

5.0

7.5

10.0

12.5

15.0

17.5

20.0

22.5

R&D investment project values

17.0

Number of units produced

30.0

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS
33

20.0

12.0

12.5

13.0

13.5

14.0

14.5

15.5

16.0

16.5

Parameter a

15.0

17.0

17.5

18.0

18.5

19.0

19.5

20.0

0.50

0.55

0.60

0.65

12.5

13.0

13.5

14.0

14.5

15.5

16.0

16.5

Parameter a

15.0

17.0

17.5

18.0

18.5

19.0

19.5

20.0

13.0

14.0

15.0

16.0

17.0

12.0

12.5

13.0

13.5

14.0

14.5

15.5

16.0

16.5

Parameter a

15.0

17.0

17.5

18.0

18.5

19.0

19.5

20.0

12.0

12.5

13.0

13.5

14.0

14.5

15.5

16.0

16.5

Parameter a

15.0

17.0

17.5

18.0

18.5

19.0

19.5

20.0

(d) Present value of costs (solid line) and revenues (dasheddotted line) in the duopoly situation with mixed strategies and
present value of costs (dashed line) and revenues (dotted line) in
the duopoly situation with war of attrition reÔ¨Ånement per unit
produced as a function of market size, a.

4.50
11.5

4.75

5.00

5.25

5.50

5.75

6.00

6.25

6.50

6.75

(b) Units produced in the duopoly situation with mixed strategies (solid line) and with war of attrition reÔ¨Ånement (dashed
line) as a function of market size, a.

11.5

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

8.0

9.0

10.0

11.0

12.0

Figure 5. Sensitivity analysis between duopoly with war of attrition reÔ¨Ånement and duopoly with mixed strategies with
respect to the market size, a.

(c) Probabilities that at least one of the duopolists complete
(solid line) and that both of the duopolists (dashed-dotted line)
complete with mixed strategies, and probabilities that at least
one of the duopolists completes (dashed line) and that both of
the duopolists (dotted line) complete with war of attrition reÔ¨Ånement as a function of market size, a.

0.00
11.5

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

12.0

(a) Values of R&D investment projects in the duopoly situation with mixed strategies (solid line) and with war of attrition
reÔ¨Ånement (dashed line) as a function of market size, a.

0.0
11.5

2.5

5.0

7.5

10.0

12.5

15.0

17.5

R&D investment project values

Probabilities of completion

Number of units produced
Values per unit produced

22.5

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS
34

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

35

The parameter a of the inverse demand function captures the number of units demanded for a given price
or the price that can be charged for a given quantity produced.29 We vary a from 11.5 up to 20 in Figure 4.
When a = 11.5, the market is so small that it is not optimal to initiate the R&D investment project even
in the monopoly situation, so that the value of the R&D investment project is zero, the number of units
produced is zero, and the probability of (economic) abandonment is 100%. When a = 12, 12.5, or 13, it is
optimal for the monopolist to initiate the R&D investment project, but the market is still not large enough
to make it optimal for both of the duopolists to initiate their R&D investment projects. However, according
to the rules of the R&D investment game given by our choice of reÔ¨Ånement criterion in the competitive R&D
phase, cf. Table 1 in Section 2, in this situation one of the Ô¨Årms‚Äô (Ô¨Årm two‚Äôs) R&D investment projects is
initiated and the other Ô¨Årm‚Äôs (Ô¨Årm one‚Äôs) R&D investment project is immediately abandoned. Thus, the
duopoly (with war of attrition reÔ¨Ånement) and monopoly situations are identical when a = 12, 12.5, or 13.
With mixed strategies both duopolists initiate their R&D investment projects at date zero when a = 12,
12.5, or 13, cf. Figure 5 for comparison between the two diÔ¨Äerent reÔ¨Ånements in the duopoly situation. When
a is 13.5 or higher, both duopolists initiate their R&D investment projects at date zero and the diÔ¨Äerences
between the duopoly and monopoly situations start arising. The scenario when a = 15 corresponds to the
base case discussed in detail above, cf. Table 3.
Figure 4(a) shows that as the size of the market increases, the values of the R&D investment projects
in both the duopoly and the monopoly situations increase, but the R&D investment project values in the
monopoly situation (solid line) increase more than in the duopoly situation (dashed line) such that the
absolute diÔ¨Äerence between the monopoly and the duopoly situations also increases. Figure 4(b) shows that
the number of units produced also increases with the market size. The increase is, however, stronger for
the duopoly situation (dashed line) than for the monopoly situation (solid line). The three reasons for a
larger production in the duopoly situation than in the monopoly situation mentioned above get stronger
the larger the size of the market. This is because as the demand increases, the better the projects are, and
therefore the later will one of the duopolists eventually abandon for economic reasons. This implies that the
diversiÔ¨Åcation eÔ¨Äects and the eÔ¨Äect that one of the duopolists completes on average earlier are increased, and
at the same time the probability that both of the duopolists complete increases. In Figure 4(d) we present
the present values of the R&D investment costs per unit produced and the present value of revenues per
units produced for both the duopoly and monopoly situations. As the size of the market increases, the price
29Our speciÔ¨Åcation of the demand function is such that the optimal quantity produced both in the monopoly and duopoly

situations is independent of a, such that there is only a price eÔ¨Äect when the size of the market is changed. Note, however, that
there is an indirect eÔ¨Äect on the quantity produced since, as the price increases, on average more R&D investment projects are
completed, which implies a higher average number of units produced.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

36

per unit sold also increases, and then also the present value of the revenue per unit produced will increase
in both the monopoly (dashed-dotted line) and the duopoly (dotted line) situations. As the present value
of revenues per unit produced increases, the Ô¨Årms are willing to incur more R&D investment costs per unit
produced in order to obtain these per unit revenues. Hence, also the present value of R&D investment costs
per unit produced increases in both the monopoly (solid line) and the duopoly (dashed line) situations. The
two inner curves correspond to the duopoly situation and the two outer curves correspond to the monopoly
situation. The diÔ¨Äerence between the two inner curves and the diÔ¨Äerence between the two outer curves are
the R&D investment project values per unit produced to the duopolist and monopolist, respectively. The
probabilities of completion are depicted in Figure 4(c). As we can see, both the probability that at least one
of the duopolists completes (dashed line) and the probability that both of the duopolists complete (dotted
line) increase with market size in absolute terms as well as relative to the monopoly situation (solid line).
Figure 5 shows that when a is 13.5 or higher there is practically no diÔ¨Äerence between the two diÔ¨Äerent
reÔ¨Ånements in the duopoly situation. The value of the R&D investment projects will always be highest with
the war of attrition reÔ¨Ånement, since this reÔ¨Ånement is the one with the highest ex-ante values. A closer
look at Figure 5(a) shows that the values with war of attrition reÔ¨Ånement (dashed line) is higher than the
values with mixed strategies reÔ¨Ånement (solid line) even for values of a at 13.5 or higher, most signiÔ¨Åcantly
for a = 13.5 and a = 14.0 when the chances for scenarios where the distinction actually matters are the
highest. It is interesting to see that when the R&D investment projects are very marginal, i.e. for a = 12,
the probability of completion as well as the number of units produced are higher for the duopoly situation
with war of attrition reÔ¨Ånement (which for this case is de facto a monopoly situation) than for the duopoly
situation with mixed strategies. Already for a = 12.5 the probabilities of completion and the number of
units produced become almost equal. For a = 13 the mixed strategy reÔ¨Ånement gives signiÔ¨Åcantly higher
probabilities of completion, more units produced, and lower price per unit produced. This is because when
the projects are very marginal the probabilities of continuing investing for each of the two Ô¨Årms with the
mixed strategy reÔ¨Ånement is low. However, when the projects are a little better (but still marginal) the
mixed strategy reÔ¨Ånement gives a higher probability that each of the projects will be completed and there
is even a small chance that both projects will be completed, cf. Figure 5(c).
The intensity of catastrophic events, Œª, measures the probability per unit of time that the value of the
R&D investment projects will vanish due to unforeseen external circumstances and thereby quantiÔ¨Åes how
challenging the R&D investment projects are. An increase in the value of Œª clearly decreases the value of the
R&D investment projects both in the duopoly and monopoly situations, but it also increases the advantage

40.0

0.01

0.02

0.03

0.05

0.06

Parameter Œª

0.04

0.07

0.08

0.09

0.10

0.80

0.90

1.00

0.02

0.03

0.05

0.06

Parameter Œª

0.04

0.07

0.08

0.09

0.10

0.01

0.02

0.03

0.05

0.06

Parameter Œª

0.04

0.07

0.08

0.09

0.10

5.50

5.75

6.00

6.25

0.02

0.03

0.05

0.06

Parameter Œª

0.04

0.07

0.08

0.09

0.10

(d) Present value of costs (solid line) and revenues (dasheddotted line) in the monopoly situation and present value of costs
(dashed line) and revenues (dotted line) in the duopoly situation per unit produced as a function of intensity of catastrophic
events, Œª.

3.25
0.00

3.50

3.75

4.00

4.25

4.50

4.75

5.00

5.25

0.01

(b) Units produced in the monopoly (solid line) and the duopoly
(dashed line) situations as a function of intensity of catastrophic
events, Œª.

0.00

0.0

2.5

5.0

7.5

10.0

12.5

15.0

17.5

20.0

22.5

25.0

Figure 6. Sensitivity analysis between duopoly with war of attrition reÔ¨Ånement and monopoly with respect to the intensity
of catastrophic events, Œª = Œª1 = Œª2 .

(c) Probabilities of completion in the monopoly situation (solid
line), probabilities that at least one of the duopolists completes
(dashed line), that both of the duopolists (dotted line) complete,
and that the second duopolist completes conditional on that the
Ô¨Årst one completes (dashed-dotted line) in the duopoly situation
as a function of intensity of catastrophic events, Œª.

0.00
0.00

0.10

0.20

0.30

0.40

0.50

0.60

0.70

0.01

(a) Values of R&D investment projects in the monopoly (solid
line) and the duopoly (dashed line) situations as a function of
intensity of catastrophic events, Œª.

0.00

0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

R&D investment project values

Probabilities of completion

Number of units produced
Values per unit produced

45.0

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS
37

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

38

that diversiÔ¨Åcation has on the R&D investment project values in the duopoly situation compared to the
monopoly situation. In Figure 6 we vary Œª for both Ô¨Årms (Œª = Œª1 = Œª2 ) from zero (no catastrophic events)
up to 0.10. When Œª = 0.10, we get the same scenario as explained above where the R&D investment project
is so marginal that only one of the two duopolists would optimally initiate investment in the R&D investment
project, and therefore the results for the monopoly and duopoly situations are identical in this scenario. (It
is also the case here that this is the only value of Œª where there is a signiÔ¨Åcant diÔ¨Äerence between the two
diÔ¨Äerent reÔ¨Ånements in the duopoly case.) For all other values of Œª in Figure 6 we get that both duopolists
optimally initiate their investment in the R&D investment project at date zero. Recall that in the base case
Œª = 0.07. Keep in mind that for this analysis we maintain the inverse demand function Ô¨Åxed, so that all
the results are due to the eÔ¨Äect that the catastrophic events have on the completion of the R&D investment
projects. Figure 6(a) shows that the value of the R&D investment projects in the monopoly situation (solid
line) is more than twice what it is in the duopoly situation (dashed line) for Œª = 0; this is mostly because
the duopolists incur much higher R&D investment costs without getting the beneÔ¨Åts of the diversiÔ¨Åcation
of the catastrophic events (since there are no catastrophic events). But when Œª increases, the value of the
R&D investment project in the monopoly situation (solid line) decreases much faster than the value of the
R&D investment projects in the duopoly situation (dashed line) mainly due to the increased diversiÔ¨Åcation
of catastrophic events in the duopoly situation. In Figure 6(b) we see that the number of units produced
decreases as Œª increases in both situations. However, the relative diÔ¨Äerence between the number of units
produced in the monopoly situation (solid line) and in the duopoly situation (dashed line) is smaller than
the relative diÔ¨Äerence between the values of the R&D investment projects because the R&D investment
duplication eÔ¨Äect does not directly inÔ¨Çuence the number of units produced.
Figure 6(d) illustrates the eÔ¨Äect of Œª on the present value of revenues and the present value of R&D
investment costs per unit produced for both the monopoly and the duopoly situations. The present value
of revenues per unit produced increases in both the monopoly (dashed-dotted line) and the duopoly (dotted
line) situations because as Œª increases, the R&D investment projects become more and more marginal and
the threshold level of the demand shocks for abandonment becomes higher, ceteris paribus. Hence, as Œª
increases the average price conditional on production occurring also increases. R&D investment costs per
unit produced also increase both in the monopoly (solid line) and the duopoly (dashed line) situations
because since the revenues per unit produced are higher, the Ô¨Årm is willing to incur higher R&D investment
costs per unit produced, but they even go up faster than the revenues per unit produced so that the project
values per unit produced go down. In Figure 6(c) we observe that the probabilities of completion decrease

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

39

as Œª increases. As a measure of the catastrophic events diversiÔ¨Åcation eÔ¨Äect we compute the conditional
probability that a monopolist would complete, given that at least one of the duopolists completes (dasheddotted line). Since the conditional probabilities decrease, the advantage of diversiÔ¨Åcation increases. This
continues until the last value of Œª, where the monopoly and duopoly situations are identical so in this case
there is no diversiÔ¨Åcation eÔ¨Äect. Even for Œª = 0 there is a small diversiÔ¨Åcation eÔ¨Äect due to the fact that
on average the surviving duopolist would be the one with the lowest realized R&D investment costs; i.e. the
duopolist with the estimated remaining R&D investment cost process that hits zero Ô¨Årst.
Figure 7 analyzes the eÔ¨Äects of changing the correlation between demand shocks and the input cost
shocks. As mentioned earlier this correlation will depend on the type of product being considered. We
change the correlation between ‚àí0.3 and +0.3. The base case has œÅyk = ‚àí0.1. Clearly, the more negative
the correlation is, the better the R&D investment projects are since this implies a higher probability that,
when R&D investment costs turn out to be low, demand is high and vice versa. De facto this gives a higher
volatility of the cash Ô¨Çows. A simple option argument implies that this results in higher values for the R&D
investment projects, higher number of units produced, and higher probabilities of completion in both the
monopoly and duopoly situations. In addition, a more negative correlation implies that on average higher
demand shocks for the cases that are completed and therefore a higher on average revenue per unit produced
both in the monopoly (dashed-dotted line) and the duopoly (dotted line) situations, cf. Figure 7(d).
Up to now we have concentrated on analyzing the eÔ¨Äect of competition on patent-protected R&D investment projects for the case where both duopolists are identical. Now we look at a particular case of
asymmetry which highlights a new angle of competition between the duopolists. In Figure 8 we change the
level of technical shocks for Ô¨Årm two, Œ≥2 , from 0.1 to 0.3 while keeping constant Ô¨Årm one‚Äôs technical shocks
at Œ≥1 = 0.2 as well as all other parameters. Figure 8 reports the valuation results of this exercise. First
note the value of the R&D investment project for a monopolist when its technical shocks change (dotted
line). As expected, higher uncertainty increases the value of the R&D investment project. This result follows
from standard real option arguments. The corresponding duopoly Ô¨Årm value (solid line) grows faster with
uncertainty than does the value of the corresponding monopoly Ô¨Årm in percentage terms. For the lowest
uncertainty in the Ô¨Ågure, Œ≥2 = 0.1, it is not optimal for Ô¨Årm two to initiate the R&D investment project
and therefore its value is zero. Most interesting, the value of Ô¨Årm one‚Äôs project (dashed line) decreases
dramatically. Recall that for this Ô¨Årm all parameters have been kept constant. We can see here that changes
in the other Ô¨Årm‚Äôs technical uncertainty have a big impact on this Ô¨Årm‚Äôs value, and all of this impact is due
to the competitive interactions between the Ô¨Årms. At Œ≥2 = 0.1, because Ô¨Årm two does not invest, Ô¨Årm one

-0.2

-0.1

0.0

Parameter œÅyk

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

8.0

9.0

10.0

11.0

12.0

0.1

0.2

-0.2

-0.1

0.00
0.0

Parameter œÅyk

0.1

0.2

0.3

0.3
-0.2

-0.1

7.0
0.0

Parameter œÅyk

0.1

0.2

-0.2

-0.1

4.50
0.0

Parameter œÅyk

0.1

0.2

(d) Present value of costs (solid line) and revenues (dasheddotted line) in the monopoly situation and present value of costs
(dashed line) and revenues (dotted line) in the duopoly situation
per unit produced as a function of correlation coeÔ¨Écient, œÅyk .

-0.3

4.75

5.00

5.25

5.50

5.75

6.00

6.25

(b) Units produced in the monopoly (solid line) and the duopoly
(dashed line) situations as a function of correlation coeÔ¨Écient,
œÅyk .

-0.3

7.5

8.0

8.5

9.0

9.5

10.0

10.5

11.0

11.5

12.0

12.5

0.3

0.3

Figure 7. Sensitivity analysis between duopoly with war of attrition reÔ¨Ånement and monopoly with respect to the correlation
coeÔ¨Écient, œÅyk .

(c) Probabilities of completion in the monopoly situation (solid
line), and probabilities that at least one of the duopolists completes (dashed line), and that both of the duopolists (dotted
line) complete in the duopoly situation as a function of correlation coeÔ¨Écient, œÅyk .

-0.3

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

0.50

(a) Values of R&D investment projects in the monopoly (solid
line) and the duopoly (dashed line) situations as a function of
correlation coeÔ¨Écient, œÅyk .

-0.3

R&D investment project values

Probabilities of completion

Number of units produced
Values per unit produced

13.0

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS
40

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

41

12.0

11.0

10.0

R&D investment project values

9.0

8.0

7.0

6.0

5.0

4.0

3.0

2.0

1.0

0.0
0.10

0.15

0.20

0.25

0.30

Parameter Œ≥2

Figure 8. Sensitivity analysis between duopoly with war of attrition reÔ¨Ånement and monopoly with respect to the level of technical shocks for Ô¨Årm two, Œ≥2 . Value of the R&D
investment project in the monopoly situation (dotted line), value of Ô¨Årm one‚Äôs R&D investment project (dashed line), value of Ô¨Årm two‚Äôs R&D investment project (solid line), and
value of both Ô¨Årms‚Äô R&D investment projects (dashed-dotted line) in the duopoly situation
as a function of the level of technical shocks for Ô¨Årm two, Œ≥2 .
becomes a monopolist. Hence, its value (dashed line) will be the same as that of the pure monopolist (dotted
line) for Œ≥2 = 0.2. In summary, as the uncertainty of Ô¨Årm two‚Äôs project increases, the value of Ô¨Årm two‚Äôs
project increases, the value of Ô¨Årm one‚Äôs project decreases, but the aggregate value of both Ô¨Årms‚Äô projects
still increases (dashed-dotted line) except for Œ≥2 = 0.1, where Ô¨Årm two does not initiate investment. This
example illustrates the importance of taking into account competitive interactions in real option valuation.
Even without any changes in the parameters of a particular Ô¨Årm, its value can vary because of changes in
the competitive environment such as changes of a parameter in a competing Ô¨Årm.

5. Conclusion
In this article we have developed a model to analyze patent-protected R&D investment projects when
there is competition in the development and marketing of the resulting product (in our case a medical
drug). The competitive interactions that occur substantially complicate the solution of the problem since
each of the duopolists has to take into account not only the factors that aÔ¨Äect its own decisions, but also

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

42

the factors that aÔ¨Äect the decisions of the other duopolist. The real options framework utilized to deal with
investments under uncertainty is extended to incorporate the game theoretic concepts required to deal with
these interactions.
Implementation of the model shows that competition in R&D in most cases not only increases production
and reduces prices, but also shortens the time of developing the product and increases the probability of a
successful development. These beneÔ¨Åts to society are countered by increased total investment costs in R&D
and lower aggregate value of the R&D investment projects. We have also seen that if the R&D investment
projects are very marginal, competition in R&D may actually harm the development if there is no mechanism
to select which of the two duopolists who should invest and who should abandon. Only in the these cases
would it be beneÔ¨Åcial to protect one single developer from competition.
Some extensions of the model would be easy to implement. For example, the current implementation of
the model assumes that both patents expire at the same date and that net cash Ô¨Çows revert to zero. It would
be trivial to add a terminal value for the R&D investment projects. It would be somewhat more diÔ¨Écult
to implement diÔ¨Äerent expiration dates for the patents in our numerical procedure, though strictly in our
formulation of the model this would be of no beneÔ¨Åt since generic drugs would be introduced as soon as the
Ô¨Årst patent expires. A more challenging task would be to increase the number of competitors, but we believe
that the qualitative nature of the results would not change.
In some sense our war of attrition reÔ¨Ånement criterion in the case of multiple Nash equilibria in the
game played by the duopolists favors the duopoly situation. This criterion says that when it is not optimal
for both duopolists to continue investing, but it would be optimal for a monopolist to continue investing,
then the duopolist with the highest value of continuing to invest will proceed investing while the other
will abandon. This reasonable rule is not just any Nash equilibrium, it is the Nash equilibrium that gives
the highest ex-ante value for the duopolist‚Äôs R&D investment projects and we motivated this choice of
reÔ¨Ånement criterion by an economic argument of mutual threats of war of attrition. It is, however, not the
only possible Nash equilibrium; mixed strategies among other equilibria would also be possible, (cf. Huisman
and Kort 1999, Huisman, Thijssen, and Kort 2001), we have also implemented this alternative and found
that unless the R&D investment project is fairly marginal, the results of the two diÔ¨Äerent implementations
are basically identical. It is also possible to think in terms of mergers and acquisitions but we have not
pursued any of these two last reÔ¨Ånements further in this article.
A more interesting and complex extension would be to add asymmetric information to the model. In the
development of the model we assumed that all participants know the value of the state variables at each

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

43

date and that they use these values to make their decisions. It is somewhat unrealistic to suppose that a
duopolist has as good an estimate of the remaining R&D investment costs to complete the other duopolist‚Äôs
project as it has of its own project. More realistically, it estimates the competitor‚Äôs cost with some error.
The model developed here could potentially help in the formulation of a public policy with respect to
the encouragement of investments in R&D. At the very least it contributes to our understanding of these
important issues in economic development.

Appendix A. The Partial Differential Equation for the Value of the Losing Firm‚Äôs
Project
The partial diÔ¨Äerential equation (PDE) corresponding to the intuitive derivation in equation (7) can be
derived by ItoÃÇ‚Äôs lemma and (other) standard arguments from stochastic control theory. Basically, the PDE
is derived by applying ItoÃÇ‚Äôs lemma to VlM 2l (Yt + dYt , Klt + dKlt , t + dt), eliminating the martingale terms
by taking the expectation under Q, and diÔ¨Äerentiating on both sides of equation (7) with respect to time,
i.e. ‚Äòdividing‚Äô by dt. Starting with the boundary condition from equation (6)
VlM 2l (y, 0, t) = VlD2 (y, t),
for y ‚â• 0 and t ‚àà [0, T ], the function VlM 2l must fulÔ¨Åll the PDE,
1 2 2 ‚àÇ 2 M 2l
‚àÇ2
œÉy y
V M 2l (y, k, t)
V
(y,
k,
t)
+
œÉ
œÉ
œÅ
yk
y
lk
yk
l
2
‚àÇy 2
‚àÇy‚àÇk l
2
1
‚àÇ
‚àÇ
2 2 ‚àÇ
+ (Œ≥l2 Il k + œÉlk
k ) 2 VlM 2l (y, k, t) + ¬µy y VlM 2l (y, k, t) + (¬µlk k ‚àí Il ) VlM 2l (y, k, t)
2
‚àÇk
‚àÇy
‚àÇk
‚àÇ
+ VlM 2l (y, k, t) ‚àí Il ‚àí (r + Œªl )VlM 2l (y, k, t) = 0,
‚àÇt

for all y ‚â• 0, k ‚â• 0, and t ‚àà [0, T ], and the free boundary condition
VlM 2l (y, k, t) ‚â• 0.
That is, the R&D investment continuation region is {(y, k, t) ‚àà R2 √ó[0, T ] : VlM 2l (y, k, t) ‚â• 0}. VlM 2l (y, k, t) <
0 is the condition for when the optimal economic abandonment decision should be taken.

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

44

Appendix B. The Partial Differential Equation for the Value of Both Firms‚Äô Projects in
the Competitive R&D Phase
The Nash equilibria in the normal form representation of the R&D investment game from Table 1 determine the functions V1R&D2 and V2R&D2 , cf. equation (15), as the following:
(16)

V1R&D2 (Yt , K1t , K2t , t) =

Ô£±
Ô£¥
Ô£¥
Ô£¥
VÃÇ1R&D2 (Yt , K1t , K2t , t)
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
V1R&D1 (Yt , K1t , t)
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£≤
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
0
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£≥

if VÃÇ1R&D2 (Yt , K1t , K2t , t) ‚â• 0 and
VÃÇ2R&D2 (Yt , K1t , K2t , t) ‚â• 0,
if (VÃÇ1R&D2 (Yt , K1t , K2t , t) ‚â• 0 and
VÃÇ2R&D2 (Yt , K1t , K2t , t) < 0) or
(V1R&D1 (Yt , K1t , t) ‚â• 0 and
V2R&D1 (Yt , K2t , t) < 0) or
(V1R&D1 (Yt , K1t , t) > V2R&D1 (Yt , K2t , t) ‚â• 0 and
VÃÇ2R&D2 (Yt , K1t , K2t , t) < 0),
if V1R&D1 (Yt , K1t , t) < 0 or
(VÃÇ1R&D2 (Yt , K1t , K2t , t) < 0 and
VÃÇ2R&D2 (Yt , K1t , K2t , t) ‚â• 0) or
(V2R&D1 (Yt , K2t , t) ‚â• V1R&D1 (Yt , K1t , t) ‚â• 0 and
VÃÇ1R&D2 (Yt , K1t , K2t , t) < 0),

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

45

and
(17)

V2R&D2 (Yt , K1t , K2t , t) =

Ô£±
Ô£¥
Ô£¥
Ô£¥VÃÇ2R&D2 (Yt , K1t , K2t , t)
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
V2R&D1 (Yt , K2t , t)
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£≤

if VÃÇ1R&D2 (Yt , K1t , K2t , t) ‚â• 0 and
VÃÇ2R&D2 (Yt , K1t , K2t , t) ‚â• 0,
if (VÃÇ1R&D2 (Yt , K1t , K2t , t) < 0 and
VÃÇ2R&D2 (Yt , K1t , K2t , t) ‚â• 0) or
(V1R&D1 (Yt , K1t , t) < 0 and
V2R&D1 (Yt , K2t , t) ‚â• 0) or
(V2R&D1 (Yt , K2t , t) ‚â• V1R&D1 (Yt , K1t , t) ‚â• 0 and

Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
0
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£≥

VÃÇ1R&D2 (Yt , K1t , K2t , t) < 0),
if V2R&D1 (Yt , K1t , t) < 0 or
(VÃÇ1R&D2 (Yt , K1t , K2t , t) ‚â• 0 and
VÃÇ2R&D2 (Yt , K1t , K2t , t) < 0) or
(V1R&D1 (Yt , K1t , t) > V2R&D1 (Yt , K2t , t) ‚â• 0 and
VÃÇ2R&D2 (Yt , K1t , K2t , t) < 0).

Equations (16) and (17) are similar in spirit to equation (8) for the optimal stopping time problem.30
The same methodology as sketched in Appendix A can be used to derive the PDEs corresponding to the
intuitive derivation in equation (15). Starting with the boundary conditions from equations (13) and (14),

30In the case of mixed strategies, Equations (16) and (17) should be substituted with

ViR&D2 (Yt , K1t , K2t , t) =

where j = 3 ‚àí i.

Ô£±
R&D2 (Y , K , K , t)
Ô£¥
t
1t
2t
Ô£¥ VÃÇi
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
ViR&D1 (Yt , Kit , t)
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£≤
Ô£¥
0
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£≥

if VÃÇ1R&D2 (Yt , K1t , K2t , t) ‚â• 0 and
VÃÇ2R&D2 (Yt , K1t , K2t , t) ‚â• 0,

if (VÃÇiR&D2 (Yt , K1t , K2t , t) ‚â• 0 and
VÃÇjR&D2 (Yt , K1t , K2t , t) < 0) or
(ViR&D1 (Yt , Kit , t) ‚â• 0 and
VjR&D1 (Yt , Kjt , t) < 0),

if ViR&D1 (Yt , Kit , t) < 0 or

(VÃÇiR&D2 (Yt , K1t , K2t , t) < 0 and
VÃÇjR&D2 (Yt , K1t , K2t , t) ‚â• 0) or

(ViR&D1 (Yt , Kit , t) ‚â• 0 and
VjR&D1 (Yt , Kjt , t) ‚â• 0 and

VÃÇiR&D2 (Yt , K1t , K2t , t) < 0),

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

46

the functions V1R&D2 and V2R&D2 must fulÔ¨Åll the PDE
‚àÇ2
1 2 2 ‚àÇ 2 R&D2
œÉy y
V
(y,
k
,
k
,
t)
+
œÉ
œÉ
œÅ
yk
V R&D2 (y, k1 , k2 , t)
1
2
y
1k
yk
1
i
2
‚àÇy 2
‚àÇy‚àÇk1 i
+ œÉy œÉ2k œÅyk yk2
+ œÉ1k œÉ2k k1 k2

2
‚àÇ2
1
2 2 ‚àÇ
ViR&D2 (y, k1 , k2 , t) + (Œ≥12 I1 k1 + œÉ1k
k1 ) 2 ViR&D2 (y, k1 , k2 , t)
‚àÇy‚àÇk2
2
‚àÇk1

2
‚àÇ2
1
2 2 ‚àÇ
ViR&D2 (y, k1 , k2 , t) + (Œ≥22 I2 k2 + œÉ2k
k2 ) 2 ViR&D2 (y, k1 , k2 , t)
‚àÇk1 ‚àÇk2
2
‚àÇk2

‚àÇ R&D2
‚àÇ R&D2
Vi
(y, k1 , k2 , t) + (¬µ1k k1 ‚àí I1 )
V
(y, k1 , k2 , t)
‚àÇy
‚àÇk1 i
‚àÇ R&D2
‚àÇ
Vi
(y, k1 , k2 , t) + ViR&D2 (y, k1 , k2 , t)
+ (¬µ2k k2 ‚àí I2 )
‚àÇk2
‚àÇt

+ ¬µy y

+ Œªj ViR&D1 (y, ki , t) ‚àí Ii ‚àí (r + Œª1 + Œª2 )ViR&D2 (y, k1 , k2 , t) = 0,
for i ‚àà {1, 2} and the free boundary conditions
V1R&D2 (y, k1 , k2 , t) ‚â• 0
and

V2R&D2 (y, k1 , k2 , t) ‚â• 0.
That is, the R&D investment continuation region for both Ô¨Årms, cf. equations (16) and (17), is {(y, k1 , k2 , t) ‚àà
R3 √ó[0, T ] : V1R&D2 (y, k1 , k2 , t) ‚â• 0 and V2R&D2 (y, k1 , k2 , t) ‚â• 0}. V1R&D2 (y, k1 , k2 , t) < 0 or V2R&D2 (y, k1 , k2 , t) <
0 is the condition for when the optimal economic abandonment decision should be taken for (at least) one
of the two Ô¨Årms. The boundary condition that gives the value to each of the two projects when the R&D
investment continuation region is left can be derived from equations (16) and (17).31
References
Baldursson, F. M. (1998): ‚ÄúIrreversible Investment Under Uncertainty in Oligopoly,‚Äù Journal of Economic Dynamics and
Control, 22, 627‚Äì644.
Bernardo, A. E., and B. Chowdhry (2002): ‚ÄúResources, Real Options, and Corporate Strategy,‚Äù Journal of Financial
Economics, 63, 211‚Äì234.
Fudenberg, D., and J. Tirole (1986): ‚ÄúA Theory of Exit in Duopoly,‚Äù Econometrica, 54(4), 943‚Äì960.
Ghemawat, P., and B. Nalebuff (1985): ‚ÄúExit,‚Äù Rand Journal of Economics, 16(2), 184‚Äì194.
31In the case of mixed strategies, the continuation region is {(y, k , k , t)
1 2

0 and V2R&D2 (y, k1 , k2 , t) ‚â•
0 and V2R&D1 (y, k2 , t) ‚â• 0)}.

0) or (V1R&D2 (y, k1 , k2 , t)

<

‚àà R3 √ó [0, T ] : (V1R&D2 (y, k1 , k2 , t) ‚â•
0 and V2R&D2 (y, k1 , k2 , t) < 0 and V1R&D1 (y, k1 , t) ‚â•

R&D INVESTMENTS WITH COMPETITIVE INTERACTIONS

47

Grenadier, S. R. (1999): ‚ÄúInformation Revelation Through Option Exercise,‚Äù The Review of Financial Studies, 12(1), 95‚Äì129.
(2002): ‚ÄúOption Exercise Games: An Application to the Equilibrium Investment Strategies of Firms,‚Äù The Review of
Financial Studies, 15(3), 691‚Äì721.
Grenadier, S. R., and A. M. Weiss (1997): ‚ÄúInvestment in Technological Innovations: An Option Pricing Approach,‚Äù Journal
of Financial Economics, 44, 397‚Äì416.
Huisman, K. J. M., and P. M. Kort (1999): ‚ÄúEÔ¨Äects of Strategic Interactions on the Option Value of Waiting,‚Äù Working
paper, Department of Economics and CentER, Tilburg University, P. O. Box 90153, 5000 LE Tilburg, The Netherlands.
Huisman, K. J. M., J. J. J. Thijssen, and P. M. Kort (2001): ‚ÄúSymmetric Equilibrium Strategies in Game Theoretical
Real Option Models,‚Äù Working paper, Department of Economics and CentER, Tilburg University, P. O. Box 90153, 5000 LE
Tilburg, The Netherlands.
Lambrecht, B. (2001): ‚ÄúThe Impact of debt Financing on Entry and Exit in a Duopoly,‚Äù The Review of Financial Studies,
14(3), 765‚Äì804.
Lambrecht, B., and W. Perraudin (1999): ‚ÄúReal Options and Preemption Under Incomplete Information,‚Äù Working paper,
University of Cambridge and Birkbeck College, London, Forthcoming in Journal of Economic Dynamics and Control.
Longstaff, F. A., and E. S. Schwartz (2001): ‚ÄúValuing American Options by Simulation: A Simple Least-Squares Approach,‚Äù The Review of Financial Studies, 14(1), 113‚Äì147.
Pawlina, G., and P. M. Kort (2001): ‚ÄúReal Options in an Asymmetric Duopoly: Who BeneÔ¨Åts From Your Competitive
Disadvantage?,‚Äù Working Paper 2001‚Äì95, Department of Economics and CentER, Tilburg University, P. O. Box 90153, 5000
LE Tilburg, The Netherlands.
Pindyck, R. S. (1993): ‚ÄúInvestments of Uncertain Cost,‚Äù Journal of Financial Economics, 34, 53‚Äì76.
Schwartz, E. S. (2001): ‚ÄúPatents and R&D as Real Options,‚Äù Working Paper #12‚Äì01, The John E. Anderson Graduate School
of Management at UCLA, Los Angeles, California 90095‚Äì1481, USA.
Schwartz, E. S., and M. Moon (2000): ‚ÄúEvaluating Research and Development Investments,‚Äù in Project Flexibility, Agency,
and Competition, chap. 6, pp. 85‚Äì106. Oxford University Press, New York, New York, USA.
Smit, H. T. J., and L. A. Ankum (1993): ‚ÄúA Real Options and Game-Theoretic Approach to Corporate Investment Strategy
Under Competition,‚Äù Financial Management, 22(3), 241‚Äì250.
Williams, J. T. (1993): ‚ÄúEquilibrium and Options on Real Assets,‚Äù The Review of Financial Studies, 6(4), 825‚Äì850.

